

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

# **BMJ Open**

#### The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting Drug Use and Outcomes: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-070615
Article Type:	Protocol
Date Submitted by the Author:	29-Nov-2022
Complete List of Authors:	MacLeod, Caitlin; NHS Tayside, Department of Vascular Surgery; University of Dundee, School of Medicine Strachan, David; NHS Tayside, Department of Vascular Surgery Radley, Andrew; University of Dundee, School of Medicine; NHS Tayside, Directorate of Public Health Khan, Faisel ; University of Dundee, School of Medicine Nagy, John; NHS Tayside, Department of Vascular Surgery Suttie, Stuart; NHS Tayside, Department of Vascular Surgery
Keywords:	Vascular surgery < SURGERY, VASCULAR SURGERY, Substance misuse < PSYCHIATRY, PUBLIC HEALTH



### The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting Drug Use and Outcomes: A Systematic Review Protocol

CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee and School of Medicine,

University of Dundee, Dundee, Scotland, UK (ORCID 0000-0002-3839-352X)

D Strachan, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK

A Radley Public Health Directorate, Kings Cross Hospital, Dundee and School of Medicine, University of Dundee, Dundee, Scotland, UK (ORCID 0000-0003-4772-2388)

F Khan, Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland, UK

J Nagy, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK

SA Suttie Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK

**Corresponding Author** 

CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee (ORCID - ORCID 0000-0002-3839-352X)

caitlin.macleod2@nhs.scot (main email address)

090001033@dundee.ac.uk

Key Words: Drug use; Vascular surgery; Infected arterial pseudoaneurysm; Health outcomes

Word count: 2470

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting Drug Use and Outcomes: A Systematic Review Protocol

#### Abstract

#### Introduction

People who inject drugs (PWID) are at risk of a range of injecting related infections and injuries, which can threaten life and limb. In parallel to escalating rates of drug-related deaths seen in Scotland and the UK, there has also been an increase in hospital admissions for skin and soft tissue infections related to injecting drug use. One such complication is the infected arterial pseudoaneurysm, which risks rupture and life-threatening haemorrhage. Surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use remain contentious, with some advocates for ligation and debridement alone, whilst others promote acute arterial reconstruction (suture or patch repair, bypass or, more recently, endovascular stent-graft placement). Rates of major lower limb amputations related to surgical management for this pathology vary in the literature. This review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including open and endovascular options, for the infected arterial pseudoaneurysm secondary to groin injecting drug use.

#### Methods and Analysis

The methods will follow the Preferred Reporting Items for Systematic reviews and Meta-Analysis checklist. Three electronic databases will be searched and resultant papers screened according to the study inclusion and exclusion criteria (detailed in the Population, Intervention, Comparison, Outcomes and Study design statement). Grey literature will be excluded. All papers at each stage will be screened by two independent authors, with disagreements arbitrated by a third. Papers will be subject to appropriate standardised quality assessments. Primary outcome: major lower limb amputation. Secondary outcomes: reintervention rate; re-bleeding rate; development of chronic limb-threatening ischaemia and mortality.

Ethics and Dissemination

This is a systematic review based upon previously conducted studies, so there are no ethical approvals required. The results of this work will be published in a peer-reviewed journal and presented at relevant conferences.

PROSPERO Registration Number 42022358209

#### Strengths and Limitations of This Study

- To our knowledge, this is the first systematic review on this topic to include primary endovascular management through placement of a stent-graft.
- The potential to find some clarity within the evidence base on patient management is of key importance, given the rising burden of disease.
- All relevant English language papers have been accessed and assessed for inclusion.
- A limitation of the study is excluding non-English language papers.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### Introduction

In recent years drug-related deaths have been rising across countries such as the United Kingdom, most markedly in Scotland, and the United States, reflecting increases in drug-related harms.<sup>1-3</sup> In parallel to these drug deaths there has also been an observed increase in hospital admissions for skin and soft tissue infections related to injecting drug use.<sup>4,5</sup> People who inject drugs (PWID) are at risk of range of injecting-related infections and injuries, some of which may threaten life and limb.<sup>6,7</sup>

One such injecting injury is the infected arterial pseudoaneurysm. A pseudoaneurysm (or false aneurysm) represents a defect in the arterial wall with haemorrhage contained by the surrounding soft tissues, compressed thrombus and not lined by endothelium.<sup>8</sup> It is distinct from a true aneurysm, which involves dilatation of the arterial wall. Continued extravasation and expansion of a pseudoaneurysm ultimately risks free rupture.<sup>9</sup> The arterial wall in PWID can also be further compromised by the severity of surrounding infection present, as well as the caustic acidifying agents injected.<sup>9-11</sup>

A pseudoaneurysm is the most commonly described arterial complication of injecting drug use. In the context of PWID, they can develop from direct trauma to an artery, usually when attempting to inject intravenously, or during intentional arterial injecting. Given the probable non-sterile injecting technique, this can lead to the formation of an intramural abscess/haematoma complex.<sup>8,12,13</sup> Arterial pseudoaneurysms may also occur as a result of malignant local infective invasion with destruction of arterial integrity from perivascular soft tissue sepsis.<sup>9,12,13</sup> A further aetiology is septic metastases, for example from infective endocarditis.<sup>9,13</sup> Arterial pseudoaneurysms in the groin are the most frequently reported in PWID resultant from injecting into this anatomical region. Although arterial pseudoaneurysms may occur anywhere throughout the arterial vasculature, usually where injecting has been undertaken.<sup>12,13</sup> If untreated they may rupture causing catastrophic, life-threatening haemorrhage.

Management options for arterial pseudoaneurysms secondary to injecting drug use remain contentious.<sup>9,12-14</sup> The options for initial operative management include: arterial ligation and

#### **BMJ** Open

debridement alone or arterial reconstruction with debridement.<sup>9,12,13,15</sup> Arterial reconstruction comprises primary repair of the defect with a suture or patch repair, or a bypass of the ligated pseudoaneurysm to compensate for the reduced distal blood supply.<sup>9,12,13,16,17</sup> Such bypasses can be routed either extra-anatomically (circumventing the infected field) or anatomically (in-situ). More recently endovascular reconstructions with stent-grafts have also been reported.<sup>18,19</sup>

However, reticence exists regarding arterial reconstruction due to the degree of pathogenic contamination common to these cases, which can risk infection of the reconstruction and predispose to life-threatening haemorrhage.<sup>14</sup> Autologous vein would usually be the preferred conduit for reconstruction, especially in an infected field, although this is often not available in PWID due to venous damage and destruction from injecting.<sup>14,17</sup> Use of the internal iliac artery as an autologous conduit has also been described.<sup>17</sup> Prosthetic grafts are high risk for infection, particularly in this setting. Biosynthetic and biologic (encompassing cadaveric) conduits are alternatives, but also risk infection.<sup>19-21</sup> An additional concern is continued injecting, introduction of further infection and also use of any reconstruction for drug-using vascular access.<sup>14,22</sup> Moreover, arterial reconstruction may not be required due to adequate residual perfusion of the limb post-ligation, and thus may pose more risk to the patient.<sup>14,15</sup> Rates of major lower limb amputation following ligation vary in the literature from 0% to 3.3% to 33%.<sup>15,23-29</sup> The purpose of this systematic review is to analyse published specific outcomes, following the different surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use. The timing of interest for these management options is immediate (at the index procedure) or during the acute admission episode. To our knowledge this is the first systematic review on this topic to incorporate endovascular reconstructions in addition to open management.

#### Objectives

This systematic review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including endovascular management, for the infected arterial pseudoaneurysm secondary to groin injecting drug use. Arterial reconstructions of interest will be those performed at the index operation and during the acute admission episode for Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

this pathology. The primary outcome will be major lower limb amputation. Secondary outcomes will be re-intervention rate, re-bleeding rate, development of chronic limb-threatening ischaemia (CLTI) and mortality.

#### Methods and Analysis

This systematic review will include all studies that meet the eligibility criteria and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) statement (Table 1).

#### Table 1. PICOS Statement.

Population	Adults (aged $\geq$ 18 years) with an infected arterial pseudoaneurysm
	secondary to groin injecting drug use (this may involve the common
	femoral, superficial femoral, profunda femoris, external iliac or
	common iliac arteries)
Intervention	Arterial reconstruction by way of repair (suture or patch repair),
	bypass operation (if ligation performed) or endovascular stent-graft
	placement +/- debridement and undertaken immediately (at the index
	surgical intervention) or during the acute admission episode
Comparison	Ligation of the infected arterial pseudoaneurysm +/- debridement
	alone at index surgical intervention
Outcomes	alone at index surgical intervention Primary outcome: Major lower limb amputation
Outcomes	alone at index surgical intervention Primary outcome: Major lower limb amputation Secondary outcomes: Re-intervention rate, re-bleeding rate,
Outcomes	alone at index surgical intervention Primary outcome: Major lower limb amputation Secondary outcomes: Re-intervention rate, re-bleeding rate, development of chronic limb-threatening ischaemia (CLTI) and
Outcomes	alone at index surgical intervention Primary outcome: Major lower limb amputation Secondary outcomes: Re-intervention rate, re-bleeding rate, development of chronic limb-threatening ischaemia (CLTI) and mortality
Outcomes Study Design	alone at index surgical intervention Primary outcome: Major lower limb amputation Secondary outcomes: Re-intervention rate, re-bleeding rate, development of chronic limb-threatening ischaemia (CLTI) and mortality Randomised controlled trials, prospective and retrospective

#### Eligibility criteria

The search will be performed in relevant electronic databases. Only full published papers in English will be included. The grey literature, encompassing conference abstracts, will be excluded.

#### Population

The population of interest are PWID who have developed infected arterial pseudoaneurysms secondary to groin injecting drug use (*i.e.* infected pseudoaneurysms related to the groin, typically due to injecting drug use in this anatomical region, and can involve the following vasculature: the common femoral, superficial femoral, profunda femoris, external iliac or common iliac arteries). PWID are defined as individuals who inject drugs, which may be illicit or prescribed, with the latter not being used in conduct with the prescription *e.g.* injection of methadone or crushed tablets in solution originally intended for oral consumption.

#### Interventions

The intervention consists of any arterial reconstruction undertaken to surgically manage an infected arterial pseudoaneurysm secondary to groin injecting drug use. This may be a suture or patch repair (the patch material may be autologous, prosthetic, biosynthetic or biologic). It also includes a bypass operation to compensate for arterial ligation of an infected arterial pseudoaneurysm (this may be performed prior to the ligation at the index intervention through an extra-anatomical route in an attempt to try and limit contamination of the reconstruction). The bypass operation may be routed extra-anatomically or anatomically and the conduit may be autologous, prosthetic, biosynthetic or biologic. Endovascular management through placement of a stent-graft across anatomically suitable pseudoaneurysms will also be incorporated into the review. The anatomical location of the pseudoaneurysm, the corresponding intervention executed and related outcomes must be reported clearly in the paper or else it will be excluded (*i.e.* if the management and outcomes of pseudoaneurysms in different anatomical locations are described cumulatively along with

each intervention and outcome, rendering those specifically related to the groin indistinguishable).

Comparison

 Arterial ligation alone with no arterial reconstruction will be considered to be the comparator.

#### Outcomes

The studies must report on the primary outcome: major lower limb amputation. Secondary outcomes of interest are: re-intervention rate; re-bleeding rate; development of CLTI and mortality.

Study design

Primary studies, which may be prospective or retrospective, in English will be included. There will be no restrictions to geographical location of the study.

Patient and public involvement

There was no direct patient and public participation in this study as it is a protocol for a systematic review.

Information sources and search strategy

The electronic databases to be systematically searched are: EMBASE; MEDLINE and Scopus. There will be no time restriction to the search (running from 1974 to search date in EMBASE, 1946 in MEDLINE and 1960 in Scopus). The search strategy was devised to fulfil the PICOS statement and employed free search terms (search strategy for each database detailed in the Supplementary Material, Appendix 1). Papers produced from the search will be limited to the English language and any grey literature identified will be excluded. Authors will not be contacted for missing data.

#### Data

#### Data selection and coding

All studies resultant from the search will be exported to EndNote 20 (Clarivate) and duplicates removed. These studies will then be transferred to Rayyan, a web-based platform to facilitate collaborative systematic literature review screening. Titles and abstracts will be independently screened by two authors (CSM and DS) in accordance with the selection criteria. Any differences during the screening process will be arbitrated by a third author (SAS) in order to reach a final decision.

The study selection process will be recorded in a Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) flow diagram.<sup>30</sup> The papers from the title and abstract screening will be then be subject to the PICOS criteria, with those not meeting these elements excluded and the reason recorded.

#### Data extraction

Data will be extracted from all studies that meet the inclusion criteria and it will be undertaken independently by two authors (CSM and DS). Any disagreements in extraction will be reviewed and decided upon by a third author (SAS). Data to be extracted are: study design; population size and basic demographics (age, gender); anatomical location of the arterial pseudoaneurysm; presentation with rupture; surgical intervention details (ligation and number of arteries ligated and information on reconstruction if performed); major lower limb amputation; need for further intervention; re-bleeding rate; development of CLTI; mortality; wound complications and follow-up duration.

Risk of bias (quality) assessment

The appropriate assessment tool will be used for the design of each study included: the Cochrane Collaboration's risk of bias tool for randomised studies (randomised controlled trials) and the Newcastle-Ottawa Scale for cohort studies and case series.<sup>31,32</sup> Evaluation using

these tools will again be performed independently by two authors (CSM and DS). Divergences in scoring will be settled by a third author (AR).

#### Synthesis and Analysis

 Data to be quantitatively synthesised are: major lower limb amputation rate; re-intervention rate; re-bleeding rate; development of CLTI and mortality. These will be calculated with the denominator as the total number of pseudoaneurysms according to management strategy (arterial ligation alone with debridement versus arterial reconstruction) for all studies with the relevant outcomes for synthesis. The robustness of the resultant evidence will be subject to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework by two authors (CSM and DS), with any differences reviewed by a third author (AR).<sup>33</sup> Heterogeneity will also be assessed using an appropriate statistical tool when the number of identified studies and the amount of variation between trials can be defined. There will also be subgroup analyses of ligation and debridement alone, compared to open and endovascular reconstructions respectively.

This systematic review protocol has also been written in accordance with the PRISMA-P checklist (Supplementary Material, Appendix 2).<sup>34,35</sup>

#### **Potential Implications**

There is no current consensus on the surgical management of the infected arterial pseudoaneurysm secondary to groin injecting drug use. This review aims to give a comprehensive and current overview of the literature and relevant outcomes to aid in informing practice.

#### **Ethics and Dissemination**

This systematic review will involve studies which have been performed and so ethical approval is not required. The review has been registered on PROSPERO and the final results

will be submitted to a peer-reviewed journal, as well as presented at relevant conferences. Any adjustments to the study protocol will be recorded on PROSPERO.

#### **Review Status**

The systematic search of the electronic databases has been undertaken, and the screening of the study titles and abstracts is underway. The review detailed in this protocol is planned to be completed in January 2023, with the report written in March 2023.

#### Funding

No funding has been received for this study.

**Competing Interest** 

None.

**Patient Consent for Publication** 

Not applicable.

**Ethical Approval** 

Judy. This study does not involve human participants.

**Provenance and Peer Review** 

Not commissioned, externally peer-reviewed.

### Acknowledgements

 We thank Scott McGregor at the University of Dundee library for advice and comments on the search strategy.

### **Author Contributions**

CSM wrote the protocol for the systematic review, has performed the initial searches and will undertake the data collection, quality assessment and will draft the systematic review paper. DS will contribute to independent data collection and quality assessments of the included papers. AR has contributed to the design of the systematic review and will guide study quality assessments and heterogeneity analyses. FK, JN and SAS have also contributed to the design of the systematic review. SAS will also arbitrate in differences between the independently assessing authors, CSM and DS. All authors have contributed to reviewing this protocol and will contribute to the final systematic review manuscript. CSM is the guarantor of the review.

#### References

- Office for National Statistics. Deaths related to drug poisoning in England and Wales: 2021 Registrations. London: Office for National Statistics, Aug 2022.
- National Records of Scotland. Drug Related Deaths in Scotland in 2021. Edinburgh: National Records of Scotland, Jul 2022.
- 3. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350.
- Lewer D, Harris M, Hope V. Opiate Injection-Associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997-2016. *Emerg Infect Dis* 2017 Aug;23(8):1400-1403.
- Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in hospitalizations for heroin-related soft tissue infections: Associations with structural market conditions. *Drug Alcohol Depend* 2016 Jun 1;163:126-33.
- 6. MacLeod CS, Senior Y, Lim J, Mittapalli D, Guthrie GJK, Suttie SA. The Needle and the Damage Done: A retrospective review of the health impact of recreational

	intravenous drug use and the collateral consequences for Vascular Surgery. Ann Vasc
	Surg 2022 Jan;78:103-111.
7.	Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of
	injecting-related injury and disease among people who inject drugs. Drug Alcohol
	Depend 2017 Feb 1;171:39-49.
8.	Cronenwett JL, Gloviczki P, Johnston KW, Kempczinski RF, Krupski WC. Rutherford's
	Vascular Surgery 2-volume set (5 <sup>th</sup> Edition). London, UK: WB Saunders Company;
	2000.
9.	Stevenson RP, Tolias C, Hussey K, Kingsmore DB. Mycotic pseudoaneurysm in
	intravenous drug users: current insights. Research Reports in Clinical Cardiology
	2019;10:1-6.
10	. Ciccarone D, Harris M. Fire in the vein: heroin acidity and its proximal effect on
	users' health. <i>Int J Drug Policy</i> 2015;26(11):1103–10.
11	. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related
	health harms and overuse of acidifiers among people who inject heroin and crack
	cocaine in London: a mixed-methods study. <i>Harm Reduct J</i> 2019 Nov 13;16(1):60.
12	. Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc
	Endovasc Surg 2006 Oct;32(4):389-96.
13	. Fiddes R, Khattab M, Abu Dakka M, Al-Khaffaf H. Patterns and management of
	vascular injuries in intravenous drug users: a literature review. Surgeon 2010
	Dec;8(6):353-61.
14	. Welch GH, Reid DB, Pollock JG. Infected false aneurysms in the groin of intravenous
	drug abusers. <i>Br J Surg</i> 1990 Mar;77(3):330-3.
15	. Quiroga E, Shalhub S, Tran NT, Starnes BW, Singh N. Outcomes of femoral artery
	ligation for treatment of infected femoral pseudoaneurysms due to drug injection. J
	Vasc Surg 2021 Feb;73(2):635-640.
16	. Padberg F Jr, Hobson R 2nd, Lee B, Anderson R, Manno J, Breitbart G, Swan K.
	Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? J Vasc
	Surg 1992 Apr;15(4):642-8.
17	. Klonaris C, Katsargyris A, Papapetrou A, Vourliotakis G, Tsiodras S, et al. Infected
	femoral artery pseudoaneurysm in drug addicts: the beneficial use of the internal
	iliac artery for arterial reconstruction. <i>J Vasc Surg</i> 2007 Mar;45(3):498-504.

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

2	
3	
4	
-	
5	
6	
7	
Q	
0	
9	
10	
11	
11	
12	
13	
14	
15	
15	
16	
17	
10	
10	
19	
20	
21	
21 22	
22	
23	
24	
25	
25	
26	
27	
28	
20	
29	
30	
31	
32	
22	
33	
34	
35	
36	
50	
37	
38	
39	
40	
40	
41	
42	
43	
44	
45	
46	
47	
4/	
48	
49	
50	
50	
51	
52	
52	
55	
54	
55	
56	
50	
5/	
58	
59	
60	
UU	

18. Fu Q, Meng X, Li F, Wang X, Cheng J, et al. Stent-graft placement with early
debridement and antibiotic treatment for femoral pseudoaneurysms in intravenous
drug addicts. Cardiovasc Intervent Radiol 2015 Jun;38(3):565-72.

- Bianchini Massoni C, Mariani E, De Troia A, Perini P, Nabulsi B, *et al*. Outcomes of Surgical and Endovascular Treatment for Arterial Lesions in Intravenous Drug Abusers. *Ann Vasc Surg* 2020 Nov;69:133-140.
- 20. Becker D, Béguin M, Weiss S, Wyss TR, Schmidli J, Makaloski V. In situ Reconstruction of Infected Groin Pseudoaneurysms in Drug Abusers With Biological Grafts. *Eur J Vasc Endovasc Surg* 2019 Oct;58(4):592-598.
- 21. Jayaraman S, Richardson D, Conrad M, Eichler C, Schecter W. Mycotic pseudoaneurysms due to injection drug use: a ten-year experience. *Ann Vasc Surg* 2012 Aug;26(6):819-24.
- 22. Georgiadis GS, Bessias NC, Pavlidis PM, Pomoni M, Batakis N, Lazarides MK. Infected false aneurysms of the limbs secondary to chronic intravenous drug abuse: analysis of perioperative considerations and operative outcomes. *Surg Today* 2007;37(10):837-44.
- 23. Mousavi SR, Saberi A, Tadayon N, Zeynalzadeh M, Kavyani A. Femoral artery ligation as treatment for infected pseudo-aneurysms, secondary to drug injection. *Acta Chir Belg* 2010 Mar-Apr;110(2):200-2.
- 24. Qiu J, Zhou W, Zhou W, Tang X, Yuan Q, *et al*. The Treatment of Infected Femoral Artery Pseudoaneurysms Secondary to Drug Abuse: 11 Years of Experience at a Single Institution. *Ann Vasc Surg* 2016 Oct;36:35-43.
- 25. DDin NU, Berlas FT, Rehman KU, Ali G, Salahuddin F, Mumtaz A. Outcomes of Femoral Artery Pseudoaneurysm in Intravenous Drug Abusers Managed at a Tertiary Care Center. *Cureus* 2021 Feb 15;13(2):e13350.
- 26. Gan JP, Leiberman DP, Pollock JG. Outcome after ligation of infected false femoral aneurysms in intravenous drug abusers. *Eur J Vasc Endovasc Surg* 2000 Feb;19(2):158-61.
- 27. Yegane RA, Salehi NA, Ghaseminegad A, Bahrami F, Bashashati M, Ahmadi M, Hojjati M. Surgical approach to vascular complications of intravenous drug abuse. *Eur J Vasc Endovasc Surg* 2006 Oct;32(4):397-401.

BMJ Open

1	
2 3	20 Nevi CA, Khao UNA, Albert C, Chab TA, Esterational descent a serie de la seldicita
4	28. Naqi SA, Khan HM, Akhtar S, Shan TA. Femoral pseudoaneurysm in drug addicts
5	excision without revascularization is a viable option. Eur J Vasc Endovasc Surg 2006
6 7	lun:31(6):585_7
8	301,31(0).303 7.
9	29. Al Shakarchi J, Wall M, Garnham A, Hobbs S, Newman J. Artery Ligation for Infected
10	Femoral Pseudoaneurysms Does Carry a High Risk of Major Amputation. Ann Vasc
12	Curr 2010 Int E0.220 220
13	Surg 2019 Jul;58:326-330.
14 15	30. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews
16	and meta-analyses: the PRISMA statement, <i>PLoS Med</i> 2009:6:e1000097.
17	
18	31. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of
20	Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,
21	2011 Available from http://bandbook.cochrane.org
22 23	
24	32. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
25	Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
26 27	meta-analyses http://www.ohri.ca/programs/clinical_enidemiology/oxford.asp
28	meta anaryses mtp.// www.onm.ca/programs/enmeal_epidermology/oxford.asp.
29	33. Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, Morton SC,
31	Viswanathan M, Bass EB, Butler M, Gartlehener G, Hartley L, McPheteers M, Morgan
32	IC Poston I Sista P. Whitlock F. Chang S. Grading the strength of a body of ovidence
33 34	Le, Reston J, Sista P, Whittock E, Chang S. Grading the strength of a body of evidence
35	when assessing health care interventions: an EPC update. J Clin Epidemiol
36	2015;68:1312e1324.
37 38	24 Shamsoor L. Mohor D. Clarko M. at al. Droforred reporting items for systematic
39	34. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
40	review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
41 42	<i>BMJ</i> 2015;349:g7647.
43	25 Mahar D. Champeon L. Clarke M. et al. Dreferred reporting items for systematic
44	35. Moner D, Shamseer L, Clarke M, <i>et al.</i> Preferred reporting items for systematic
45 46	review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
47	
48	
49 50	
51	
52	
55 54	
55	
56	

**Supplementary Material** 

Appendix 1

Search Strategy for EMBASE, MEDLINE and Scopus

("Pseudoan\*" OR "Pseudo-an" OR "False an\*")

AND

("Femoral\*" OR "Groin")

AND

("Intrav\* drug use\*" OR "Intrav\* drug abuse\*" OR "Intrav\* drug misuse\*" OR "Intrav\* drug addict\*" OR "Drug use\*" OR "Drug abuse\*" OR "Drug misuse\*" OR "Drug addict\*" OR "Substance use\*" OR "Substance abuse\*" OR "Substance misuse\*" OR Inject\* adj3 drug\*)

			ludin
PRISMA-P (Prefer a systematic revi	rred Ro ew pro	eporting otocol*	Items for Systematic review and Meta-Analysis Protocols) 2015 checkម្ហ៊ីst:ដ្អីecommended items to addi ធ្លូ ៣ដ្ឋ
Section and topic	ltem No	Page No	Checklist item
ADMINISTRATIVE IN	FORMA	TION	
Title:			
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration and registration
Authors:			
Contact	3a	1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide provi
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review 🛱 💆
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published preciously, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:			an is
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the proposition of the
INTRODUCTION			
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, compared outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review

Page

			BMJ Open Sp P
			-2022-07
Information sources	9	8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
Search strategy	10	16	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Study records:			
Data management	11a	8-10	Describe the mechanism(s) that will be used to manage records and data throughou and ata throughou at the ata th
Selection process	11b	8-10	State the process that will be used for selecting studies (such as two independent reduced as the process that will be used for selecting studies (such as two independent reduced as the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c	8-10	Describe planned method of extracting data from reports (such as piloting forms, do give independently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	12	9	List and define all variables for which data will be sought (such as PICO items, funding $\frac{1}{2}$ by the ces), any pre-planned data assumptions and simplifications
Outcomes and prioritization	13	8,10	List and define all outcomes for which data will be sought, including prioritisation of additional outcomes, with rationale
Risk of bias in individual studies	14	10	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	15a	10	Describe criteria under which study data will be quantitatively synthesised
	15b	10	If data are appropriate for quantitative synthesis, describe planned summary measures, and the set of the set
	15c	10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, and the series of the second
	15d	N/A	If quantitative synthesis is not appropriate, describe the type of summary planned
Meta-bias(es)	16	N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within studies)
Confidence in cumulative evidence	17	10	Describe how the strength of the body of evidence will be assessed (such as GRADE) 2 1 20 20 20 20 20 20 20 20 20 20 20 20 20
* It is strongly recom	mendeo	d that this	s checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification
distributed under a C	Creative	Common	is Attribution Licence 4.0.
From <sup>.</sup> Shamseer I M	oher D	Clarke M	ö Ghersi D. Liberati A. Petticrew M. Shekelle P. Stewart I. PRISMA-P. Group. Preferred reportion items for systematic review and meta-
analysis protocols (PF	RISMA-P	elance III, 2015: el	laboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.
			ra phi
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml 🔴



			BMJ Open BMJ
PRISMA-P (Prefer a systematic revio	rred Re ew pro	eporting   otocol*	tems for Systematic review and Meta-Analysis Protocols) 2015 check සින්දා මීecommended items to address in
Section and topic	ltem No	Page No	ច្នុង Checklist item ថ្មី ភ ទួក្ខ
ADMINISTRATIVE IN	FORMA	TION	s reig
Title:		4.0	hteme
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	د ۵۲	N/A	If registered, provide the name of the registry (such as PROSPERO) and registration as the registry of the registry (such as PROSPERO) and registration as the registry of the
	2	3	if registered, provide the name of the registry (such as PROSPERO) and registration multipleer
Contact	3a	1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide special mailing address of corresponding author
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:			aini.
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the proposol
INTRODUCTION			ar te
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known 🗸 💈 📩
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to barticipants, interventions, comparators, and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9	8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Page 21 of 22

24

26

34

44 45

			BMJ Open by Biopen
	10	10	Ji 20 Drocent dreft of coarch stratery to be used for at least one electronic database ling(Clim Oplanned limits such that it could be
Search strategy	10	16	repeated
Study records: Data management	11a	8-10	Describe the mechanism(s) that will be used to manage records and data throughout the review
Selection process	11b	8-10	State the process that will be used for selecting studies (such as two independent review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c	8-10	Describe planned method of extracting data from reports (such as piloting forms, dong independently, in duplicate), any process for obtaining and confirming data from investigators
Data items	12	9	List and define all variables for which data will be sought (such as PICO items, funding for ces), any pre-planned data assumptio and simplifications
Outcomes and prioritization	13	8,10	List and define all outcomes for which data will be sought, including prioritisation of signation additional outcomes, with rationa
Risk of bias in individual studies	14	10	Describe anticipated methods for assessing risk of bias of individual studies, includin with this will be done at the outcome study level, or both; state how this information will be used in data synthesis
Data synthesis	15a	10	Describe criteria under which study data will be quantitatively synthesised 📃 🧕 🧕
	15b	10	If data are appropriate for quantitative synthesis, describe planned summary measures, whethods of handling data and methods combining data from studies, including any planned exploration of consistency (suches subject of the second structures of the second structure structure structure structures of the second structure structures of the second structure structure structures of the second structure structure structure structure structure structures of the second structure structure structure structure structure structure structure structure structures at the second structure structure structure structure structure structure structure structure structure structures structure structures structure struc
	15c	10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses Aneta - regression)
	15d	N/A	If quantitative synthesis is not appropriate, describe the type of summary planned 👸 💈
Meta-bias(es)	16	N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across stu
Confidence in cumulative evidence	17	10	Describe how the strength of the body of evidence will be assessed (such as GRADE) ar technology to be a second
* It is strongly recom on the items. Ameno distributed under a (	imended dments to Creative	l that this to a revie Common	s checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification w protocol should be tracked and dated. The copyright for PRISMA-P (including checking sheld by the PRISMA-P Group and is ns Attribution Licence 4.0.
From: Shamseer L, M analysis protocols (Pi	loher D, ( RISMA-P)	Clarke M, ) 2015: el	. Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and met laboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.
			ographi iq



# **BMJ Open**

#### The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting Drug Use and Outcomes: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-070615.R1
Article Type:	Protocol
Date Submitted by the Author:	03-May-2023
Complete List of Authors:	MacLeod, Caitlin; NHS Tayside, Department of Vascular Surgery; University of Dundee, School of Medicine Strachan, David; NHS Tayside, Department of Vascular Surgery Radley, Andrew; University of Dundee, School of Medicine; NHS Tayside, Directorate of Public Health Khan, Faisel ; University of Dundee, School of Medicine Nagy, John; NHS Tayside, Department of Vascular Surgery Suttie, Stuart; NHS Tayside, Department of Vascular Surgery
<b>Primary Subject Heading</b> :	Surgery
Secondary Subject Heading:	Addiction, Cardiovascular medicine, Public health, Infectious diseases, Global health
Keywords:	Vascular surgery < SURGERY, VASCULAR SURGERY, Substance misuse < PSYCHIATRY, PUBLIC HEALTH, Surgical pathology < PATHOLOGY

SCHOLARONE<sup>™</sup> Manuscripts Page 1 of 23

1

BMJ Open

2									
4	1	The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting							
5 6	2	Drug Use and Outcomes: A Systematic Review Protocol							
7	3								
8 9	4	CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee and School of Medicine,							
10 11 12 13 14	5	University of Dundee, Dundee, Scotland, UK (ORCID 0000-0002-3839-352X)							
	6	D Strachan, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK							
	7	A Radley Public Health Directorate, Kings Cross Hospital, Dundee and School of Medicine, University							
15 16	8	of Dundee, Dundee, Scotland, UK (ORCID 0000-0003-4772-2388)							
17 19	9	F Khan, Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland,							
18	10	UK							
20 21	11	J Nagy, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK							
22	12	SA Suttie Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK							
23	13								
25 26	14								
27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	15	Corresponding Author							
	16	CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee (ORCID - ORCID 0000-							
	17	0002-3839-352X)							
	18	<u>caitlin.macleod2@nhs.scot</u> (main email address)							
	19	090001033@dundee.ac.uk							
	20								
	21								
	22	Key Words: Drug use; Vascular surgery; Infected arterial pseudoaneurysm; Health outcomes							
	23								
	24	Word count: 2462							
45 46	25								
47 49									
48 49									
50 51									
52									
53 54									
55 56									
57									
58 59									
60									

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting **Drug Use and Outcomes: A Systematic Review Protocol** 

Abstract

Introduction

People who inject drugs (PWID) are at risk of a range of injecting-related infections and injuries, which can threaten life and limb. In parallel to escalating rates of drug-related deaths seen in Scotland and the UK, there has also been an increase in hospital admissions for skin and soft tissue infections related to injecting drug use. One such injecting complication is the infected arterial pseudoaneurysm, which risks rupture and life-threatening haemorrhage. Surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use remain contentious, with some advocates for ligation and debridement alone, whilst others promote acute arterial reconstruction (suture or patch repair, bypass or, more recently, endovascular stent-graft placement). Rates of major lower limb amputations related to surgical management for this pathology vary in the literature. This review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including open and endovascular options, for the infected arterial pseudoaneurysm secondary to groin injecting drug use.

Methods and Analysis

The methods will follow the Preferred Reporting Items for Systematic reviews and Meta-Analysis checklist. Three electronic databases will be searched and the resultant papers screened according to the study inclusion and exclusion criteria (detailed in the Population, Intervention, Comparison, Outcomes and Study design statement). Grey literature will be excluded. All papers at each stage will be screened by two independent authors, with disagreements arbitrated by a third. Papers will be subject to appropriate standardised quality assessments. Primary outcome: major lower limb amputation. Secondary outcomes: re-intervention rate; re-bleeding rate; development of chronic limb-threatening ischaemia 30-day mortality and claudication.

Page 3 of 23

2				
3 4	1	Ethics and Dissemination		
5	2	This is a systematic review based upon previously conducted studies, therefore no ethical		
7	3	approval is required. The results of this work will be published in a peer-reviewed journal and		
8 9	4	presented at relevant conferences.		
10 11	5			
12 13	6	PROSPERO Registration Number CRD42022358209		
14	7			
15 16	8	Strengths and Limitations of This Study		
17 18	9			
19 20	10	• A comprehensive review of operative management methods for this pathology.		
21	11	• The inclusion of primary endovascular stept-graft placement as a treatment modality.		
22	12	All relevant English language namers will be accessed and assessed for inclusion		
24 25	12	A limitation of the study is evoluting non English language papers and grow literature		
26 27	14	• A limitation of the study is excluding non-english language papers and grey interature.		
28 29	14			
30	15			
31 32				
33 34				
35 36				
37				
38 39				
40 41				
42 43				
44				
45 46				
47 48				
49 50				
51				
52 53				
54 55				
56 57				
58				
59 60				

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

#### 

#### Introduction

In recent years drug-related deaths have been rising across countries such as the United Kingdom, most markedly in Scotland, and the United States, reflecting increases in drugrelated harms.<sup>1-3</sup> In parallel to these drug deaths there has also been an observed increase in hospital admissions for skin and soft tissue infections related to injecting drug use.<sup>4,5</sup> People who inject drugs (PWID) are at risk of range of injecting-related infections and injuries, some of which may threaten life and limb.<sup>6,7</sup>

One such injecting injury is the infected arterial pseudoaneurysm. A pseudoaneurysm (or false aneurysm) represents a defect in the arterial wall with haemorrhage contained by the surrounding soft tissues, compressed thrombus and not lined by endothelium.<sup>8</sup> It is distinct from a true aneurysm, which involves dilatation of the arterial wall. Continued extravasation and expansion of a pseudoaneurysm ultimately risks free rupture.<sup>9</sup> The arterial wall in PWID can also be further compromised by the severity of surrounding infection present, as well as the caustic acidifying agents injected.<sup>9-12</sup> 

A pseudoaneurysm is the most commonly described arterial complication of injecting drug use. In the context of PWID, they can develop from direct, typically infective, trauma to an artery, usually when attempting to inject intravenously, or during intentional arterial injecting. Given the probable non-sterile injecting technique, this can lead to the formation of an intramural abscess/haematoma complex.<sup>8,9,13,14</sup> Arterial pseudoaneurysms may also occur as a result of malignant local infective invasion with destruction of arterial integrity from perivascular soft tissue sepsis.<sup>9,10,12,13</sup> A further aetiology is septic metastases, for example from infective endocarditis.<sup>10,14</sup> Arterial pseudoaneurysms in the groin are the most frequently reported in PWID resultant from injecting into this anatomical region. However arterial pseudoaneurysms may occur anywhere throughout the arterial vasculature, usually where injecting has been undertaken.<sup>13,14</sup> If untreated they may rupture causing catastrophic, life-threatening haemorrhage.

Management options for arterial pseudoaneurysms secondary to injecting drug use remain contentious.<sup>10,13-15</sup> The options for initial operative management include: arterial ligation and 

Page 5 of 23

#### **BMJ** Open

debridement alone or arterial reconstruction with debridement.<sup>10,13,14,16</sup> Arterial reconstruction comprises primary repair of the defect with a suture or patch repair, or a bypass of the ligated pseudoaneurysm to compensate for the reduced distal blood supply.<sup>10,13,14,17,18</sup> Such bypasses can be routed either extra-anatomically (circumventing the infected field) or anatomically (in-situ). More recently endovascular reconstructions with stent-grafts have also been reported.<sup>19,20</sup>

However, reticence exists regarding arterial reconstruction due to the degree of pathogenic contamination common to these cases, which can risk infection of the reconstruction and predispose to life-threatening haemorrhage.<sup>15</sup> Autologous vein would usually be the preferred conduit for reconstruction, especially in an infected field, although this is often not available in PWID due to venous damage and destruction from injecting.<sup>15,18</sup> Use of the internal iliac artery as an autologous conduit has also been described.<sup>18</sup> Prosthetic grafts are high risk for infection, particularly in this setting. Biosynthetic and biologic (encompassing cadaveric) conduits are alternatives, but also risk infection.<sup>20-22</sup> An additional concern is continued injecting, introduction of further infection and also use of any reconstruction for drug-using vascular access.<sup>15,23</sup> Moreover, arterial reconstruction may not be required due to adequate residual perfusion of the limb post-ligation, and thus may pose more risk to the patient.<sup>15,16</sup> Rates of major lower limb amputation following ligation vary in the literature from 0% to 3.3% to 33%.<sup>16,24-30</sup> The purpose of this systematic review is to analyse published specific outcomes, following the different surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use. The timing of interest for these management options is immediate (at the index procedure) or during the acute admission episode (non-immediate). To our knowledge this is the first systematic review on this topic to incorporate endovascular reconstructions in addition to open management.

27 Objectives

This systematic review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including endovascular management, for the infected arterial pseudoaneurysm secondary to groin injecting drug use. Arterial reconstructions of interest will be those performed at the index operation and during the acute admission episode for

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**BMJ** Open

this pathology. The primary outcome will be major lower limb amputation. Secondary
outcomes will be re-intervention rate, re-bleeding rate, development of chronic limbthreatening ischaemia (CLTI), 30-day mortality and claudication.

Methods and Analysis

This systematic review will include all studies that meet the Population, Intervention, Comparison, Outcomes and Study design (PICOS) statement (Table 1) and eligibility criteria.

Table 1. PICOS Statement.

Population	Adults (aged $\geq$ 18 years) with an infected arterial pseudoaneurysm
	secondary to grain injecting drug use (this may involve the common
	secondary to grow injecting drug use (this may involve the common
	femoral, superficial femoral, profunda femoris, external iliac or
	common iliac arteries)
Intervention	Arterial reconstruction by way of repair (suture or patch repair),
	bypass operation (if ligation performed) or endovascular stent-graft
	placement +/- debridement and undertaken immediately (at the index
	surgical intervention) or during the acute admission episode
Comparison	Ligation of the infected arterial pseudoaneurysm +/- debridement
	alone at index surgical intervention
Outcomes	Primary outcome: Major lower limb amputation
	Secondary outcomes: Re-intervention rate; re-bleeding rate;
	development of chronic limb-threatening ischaemia (CLTI); 30-day
	mortality and claudication
Study Design	Randomised controlled trials, prospective and retrospective
	observational cohort studies and case series (four or more patients)

#### 1 Eligibility criteria

The search will be performed in relevant electronic databases. Only full published papers in English will be included. The grey literature, encompassing conference abstracts, will be excluded. The anatomical location of the pseudoaneurysm, the corresponding intervention executed and related outcomes must be reported clearly in the paper or else it will be excluded (*i.e.* if the management and outcomes of pseudoaneurysms in different anatomical locations are described cumulatively along with each intervention and outcome, rendering those specifically related to the groin indistinguishable). Papers that detail only some of the outcomes of interest, however distinctly report the related management method for the correct anatomical area will be included with documentation of the outcomes reported on, and "Not reported" or "Unclear" as applicable.

14 Population

29 15

The population of interest are PWID who have developed infected arterial pseudoaneurysms secondary to groin injecting drug use (i.e. infected pseudoaneurysms related to the groin, typically due to injecting drug use in this anatomical region, and can involve the following vasculature: the common femoral, superficial femoral, profunda femoris, external iliac or common iliac arteries). The case definition will be any arterial pseudoaneurysm secondary to groin injecting drug use. Cases will be ascertained on radiological findings (if imaging performed) and clinically, including at the time of operation. All arterial pseudoaneurysms in this review will be considered infected due to the aetiology. Non-sterile injecting predominantly precipitates the ensuing pathophysiology in these cases, which is typically infective rather than simply traumatic.<sup>9</sup> PWID are defined as individuals who inject drugs, which may be illicit or prescribed, with the latter not being used in conduct with the prescription e.g. injection of methadone or crushed tablets in solution originally intended for oral consumption.

- <sup>58</sup> 31
- 60 32

1	Interventions
-	miller ventions

The intervention consists of any arterial reconstruction undertaken to surgically manage an infected arterial pseudoaneurysm secondary to groin injecting drug use. This may be a suture or patch repair (the patch material may be autologous, prosthetic, biosynthetic or biologic). It also includes a bypass operation to compensate for arterial ligation of an infected arterial pseudoaneurysm (this may be performed prior to the ligation at the index intervention through an extra-anatomical route in an attempt to try and limit contamination of the reconstruction). The bypass operation may be routed extra-anatomically or anatomically and the conduit may be autologous, prosthetic, biosynthetic or biologic. Endovascular management through placement of a stent-graft across anatomically suitable pseudoaneurysms will also be incorporated into the review. Comparison Arterial ligation alone with no arterial reconstruction will be considered to be the comparator. Outcomes The studies should report on the primary outcome: major lower limb amputation. Secondary outcomes of interest are: re-intervention rate; re-bleeding rate; development of CLTI, 30-day mortality and claudication. Study design Primary studies, which may be prospective or retrospective, in English will be included. There will be no restrictions to geographical location of the study. Patient and public involvement There was no direct patient and public participation in this study as it is a protocol for a systematic review.

1 2		
3 4	1	Information sources and search strategy
5	2	
7	3	The electronic databases to be systematically searched are: EMBASE; MEDLINE and Scopus.
8 9	4	There will be no time restriction to the search (running from 1974 to search date in EMBASE,
10 11	5	1946 in MEDLINE and 1960 in Scopus). The search strategy was devised to fulfil the PICOS
12 13	6	statement and employed free search terms (search strategy for each database detailed in the
14 15	7	Supplementary Material, Appendix 1). Papers produced from the search will be limited to the
16	8	English language and any grey literature identified will be excluded. Authors of recent
18	9	publications may be contacted for missing data.
19 20	10	
21 22	11	Data
23 24	12	
25 26	13	Data selection and coding
27	14	
29	15	All studies resultant from the search will be exported to EndNote 20 (Clarivate) and duplicates
30 31	16	removed. These studies will then be transferred to Rayyan, a web-based platform to facilitate
32 33	17	collaborative systematic literature review screening. <sup>31</sup> Titles and abstracts will be
34 35	18	independently screened by two authors (CSM and DS) in accordance with the selection
36 37	19	criteria. Any differences during the screening process will be arbitrated by a third author
38 39	20	(JN/SAS/AR) in order to reach a final decision.
40	21	
41 42	22	The study selection process will be recorded in a Preferred Reporting Items for Systematic
43 44	23	reviews and Meta-Analysis (PRISMA) flow diagram. <sup>32</sup> The papers from the title and abstract
45 46	24	screening will be then be subject to the PICOS criteria, with those not meeting these elements
47 48	25	excluded and the reason recorded.
49 50	26	
50 51	27	Data extraction
52 53	28	
54 55	29	Data will be extracted from all studies that meet the inclusion criteria and it will be
56 57	30	undertaken independently by two authors (CSM and DS). Any disagreements in extraction will
58 59	31	be reviewed and decided upon by a third author (JN/SAS/AR). Data to be extracted are: study
60	32	design; population size and basic demographics (age, gender); anatomical location of the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

arterial pseudoaneurysm; presentation with rupture; surgical intervention details (ligation
and number of arteries ligated and information on reconstruction if performed); major lower
limb amputation; need for further intervention; re-bleeding rate; development of CLTI; 30day mortality; claudication; wound management; wound complications and follow-up
duration. For the arterial reconstructions, graft infections and thromboses will also be
recorded. If reported, the clinical status of the patient at presentation and influence of this
on management will also be documented.

9 Risk of bias (quality) assessment

11 The appropriate assessment tool will be used for the design of each study included: the 12 Cochrane Collaboration's risk of bias tool for randomised studies (randomised controlled 13 trials), the Newcastle-Ottawa Scale for cohort studies and the Joanna Briggs Institute critical 14 appraisal tool for case series.<sup>33-35</sup> Evaluation using these tools will again be performed 15 independently by two authors (CSM and DS). Divergences in scoring will be settled by a third 16 author (AR/JN/SAS).

N.C

18 Synthesis and Analysis

Data to be quantitatively synthesised are: major lower limb amputation rate; re-intervention rate; re-bleeding rate; development of CLTI, 30-day mortality and claudication. Data for each outcome will be quantitatively pooled and assessed using suitable statistical tools and models (i.e. proportional and conventional comparative meta-analyses). The robustness of the resultant evidence will be subject to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework by two authors (CSM and DS), with any differences reviewed by a third author (AR/JN/SAS).<sup>36</sup> Heterogeneity will also be assessed using an appropriate statistical tool when the number of identified studies and the amount of variation between trials can be defined. If the data allows, there will also be subgroup analyses of ligation and debridement alone, compared to open and endovascular reconstructions respectively. 

BMJ Open

2		
3 4	1	This systematic review protocol has also been written in accordance with the PRISMA-P
5 6	2	checklist (Supplementary Material, Appendix 2). <sup>37,38</sup>
7	3	
8 9	4	Potential Implications
10 11	5	
12 13	6	There is no current consensus on the surgical management of the infected arterial
14 15	7	pseudoaneurysm secondary to groin injecting drug use. This review aims to give a
16 17	8	comprehensive and contemporary overview of the literature and relevant outcomes to aid in
17	9	informing practice.
19 20	10	
21 22	11	Ethics and Dissemination
23 24	12	
25 26	13	This systematic review will involve studies which have been performed and so ethical
27	14	approval is not required. The review has been registered on PROSPERO and the final results
28 29	15	will be submitted to a peer-reviewed journal, as well as presented at relevant conferences.
30 31	16	Any adjustments to the study protocol will be recorded on PROSPERO.
32 33	17	
34 35	18	Review Status
36 37	19	
38	20	The systematic search of the electronic databases has been undertaken, and the screening of
40	21	the study titles and abstracts is underway. The review detailed in this protocol is planned to
41 42	22	be completed in January 2023, with the report written in April 2023.
43 44	23	
45 46	24	Funding
47 48	25	
49 50	26	No funding has been received for this study.
50 51	27	
52 53	28	Competing Interest
54 55	29	
56 57	30	None.
58 50	31	
60	32	
Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

1 2		
3	1	Patient Consent for Publication
4 5	2	
6 7 8 9 10 11 12 13	3	Not applicable.
	4	
	5	Ethical Approval
	6	
14 15	7	This study does not involve human participants.
16 17 18 19 20 21 22 23 24 25 26 27 28 29 30	8	
	9	Provenance and Peer Review
	10	
	11	Not commissioned, externally peer-reviewed.
	12	
	13	Acknowledgements
	14	
	15	We thank Scott McGregor at the University of Dundee library for advice and comments on
31 22	16	the search strategy.
32 33	17	
34 35	18	Author Contributions
36 37	19	
38 39	20	CSM wrote the protocol for the systematic review, has performed the initial searches and will
40	21	undertake the data collection, quality assessment and will draft the systematic review paper.
41 42 43 44 45 46 47 48 49 50 51 51	22	DS will contribute to independent data collection and quality assessments of the included
	23	papers. AR has contributed to the design of the systematic review and will guide study quality
	24	assessments and heterogeneity analyses. FK, JN and SAS have also contributed to the design
	25	of the systematic review. JN, SAS and AR will also arbitrate in differences between the
	26	independently assessing authors, CSM and DS. All authors have contributed to reviewing this
	27	protocol and will contribute to the final systematic review manuscript. CSM is the guarantor
53	28	of the review.
54 55	29	
56 57	30	
58 59	31	
60	32	

2		
4	1	References
5 6	2	
7 8	3	1. Office for National Statistics. Deaths related to drug poisoning in England and Wales:
9	4	2021 Registrations. London: Office for National Statistics, Aug 2022.
10 11	5	2. National Records of Scotland. Drug Related Deaths in Scotland in 2021. Edinburgh:
12 13	6	National Records of Scotland, Jul 2022.
14 15	7	3. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid
16 17	8	overdose crisis. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350.
18	9	4. Lewer D, Harris M, Hope V. Opiate Injection-Associated Skin, Soft Tissue, and
19 20	10	Vascular Infections, England, UK, 1997-2016. Emerg Infect Dis 2017 Aug;23(8):1400-
21 22	11	1403.
23 24	12	5. Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in
25 26	13	hospitalizations for heroin-related soft tissue infections: Associations with structural
27 20	14	market conditions. Drug Alcohol Depend 2016 Jun 1;163:126-33.
20 29	15	6. MacLeod CS, Senior Y, Lim J, Mittapalli D, Guthrie GJK, Suttie SA. The Needle and the
30 31	16	Damage Done: A retrospective review of the health impact of recreational
32 33	17	intravenous drug use and the collateral consequences for Vascular Surgery. Ann Vasc
34 35	18	Surg 2022 Jan;78:103-111.
36 37	19	7. Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of
38 39	20	injecting-related injury and disease among people who inject drugs. Drug Alcohol
40 41	21	Depend 2017 Feb 1;171:39-49.
42	22	8. Cronenwett JL, Gloviczki P, Johnston KW, Kempczinski RF, Krupski WC. Rutherford's
43 44	23	Vascular Surgery 2-volume set (5 <sup>th</sup> Edition). London, UK: WB Saunders Company;
45 46	24	2000.
47 48	25	9. Anderson CB, Butcher HR, Ballinger WF. Mycotic Aneurysms. Arch Surg 1974;
49 50	26	109(5):712-717.
51 52	27	10. Stevenson RP, Tolias C, Hussey K, Kingsmore DB. Mycotic pseudoaneurysm in
53	28	intravenous drug users: current insights. Research Reports in Clinical Cardiology
54 55	29	2019;10:1-6.
56 57	30	11. Ciccarone D, Harris M. Fire in the vein: heroin acidity and its proximal effect on
58 59 60	31	users' health. Int J Drug Policy 2015;26(11):1103–10.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

3 4	1	12. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related
5	2	health harms and overuse of acidifiers among people who inject heroin and crack
7	3	cocaine in London: a mixed-methods study. Harm Reduct J 2019 Nov 13;16(1):60.
8 9	4	13. Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc
10 11	5	Endovasc Surg 2006 Oct;32(4):389-96.
12 13	6	14. Fiddes R, Khattab M, Abu Dakka M, Al-Khaffaf H. Patterns and management of
14 15	7	vascular injuries in intravenous drug users: a literature review. Surgeon 2010
16 17	8	Dec;8(6):353-61.
17	9	15. Welch GH, Reid DB, Pollock JG. Infected false aneurysms in the groin of intravenous
19 20	10	drug abusers. Br J Surg 1990 Mar;77(3):330-3.
21 22	11	16. Quiroga E, Shalhub S, Tran NT, Starnes BW, Singh N. Outcomes of femoral artery
23 24	12	ligation for treatment of infected femoral pseudoaneurysms due to drug injection. J
25 26	13	Vasc Surg 2021 Feb;73(2):635-640.
27	14	17. Padberg F Jr, Hobson R 2nd, Lee B, Anderson R, Manno J, Breitbart G, Swan K.
20	15	Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? J Vasc
30 31	16	Surg 1992 Apr;15(4):642-8.
32 33	17	18. Klonaris C, Katsargyris A, Papapetrou A, Vourliotakis G, Tsiodras S, et al. Infected
34 35	18	femoral artery pseudoaneurysm in drug addicts: the beneficial use of the internal
36 37	19	iliac artery for arterial reconstruction. <i>J Vasc Surg</i> 2007 Mar;45(3):498-504.
38 39	20	19. Fu Q, Meng X, Li F, Wang X, Cheng J, et al. Stent-graft placement with early
40	21	debridement and antibiotic treatment for femoral pseudoaneurysms in intravenous
41	22	drug addicts. Cardiovasc Intervent Radiol 2015 Jun;38(3):565-72.
43 44	23	20. Bianchini Massoni C, Mariani E, De Troia A, Perini P, Nabulsi B, et al. Outcomes of
45 46	24	Surgical and Endovascular Treatment for Arterial Lesions in Intravenous Drug
47 48	25	Abusers. Ann Vasc Surg 2020 Nov;69:133-140.
49 50 51	26	21. Becker D, Béguin M, Weiss S, Wyss TR, Schmidli J, Makaloski V. In situ Reconstruction
	27	of Infected Groin Pseudoaneurysms in Drug Abusers With Biological Grafts. Eur J
52	28	Vasc Endovasc Surg 2019 Oct;58(4):592-598.
54 55	29	22. Jayaraman S, Richardson D, Conrad M, Eichler C, Schecter W. Mycotic
56 57	30	pseudoaneurysms due to injection drug use: a ten-year experience. Ann Vasc Surg
58 59	31	2012 Aug;26(6):819-24.
60		

Page 15 of 23

1

2		
3 4	1	23. Georgiadis GS, Bessias NC, Pavlidis PM, Pomoni M, Batakis N, Lazarides MK. Infected
5 6	2	false aneurysms of the limbs secondary to chronic intravenous drug abuse: analysis
7 8	3	of perioperative considerations and operative outcomes. Surg Today
9	4	2007;37(10):837-44.
10 11 12 13 14 15	5	24. Mousavi SR, Saberi A, Tadayon N, Zeynalzadeh M, Kavyani A. Femoral artery ligation
	6	as treatment for infected pseudo-aneurysms, secondary to drug injection. Acta Chir
	7	<i>Belg</i> 2010 Mar-Apr;110(2):200-2.
16 17	8	25. Qiu J, Zhou W, Zhou W, Tang X, Yuan Q, <i>et al</i> . The Treatment of Infected Femoral
18	9	Artery Pseudoaneurysms Secondary to Drug Abuse: 11 Years of Experience at a
19 20	10	Single Institution. Ann Vasc Surg 2016 Oct;36:35-43.
21 22	11	26. DDin NU, Berlas FT, Rehman KU, Ali G, Salahuddin F, Mumtaz A. Outcomes of
23 24	12	Femoral Artery Pseudoaneurysm in Intravenous Drug Abusers Managed at a Tertiary
25 26	13	Care Center. <i>Cureus</i> 2021 Feb 15;13(2):e13350.
27 28 29 30 31	14	27. Gan JP, Leiberman DP, Pollock JG. Outcome after ligation of infected false femoral
	15	aneurysms in intravenous drug abusers. Eur J Vasc Endovasc Surg 2000
	16	Feb;19(2):158-61.
32 33	17	28. Yegane RA, Salehi NA, Ghaseminegad A, Bahrami F, Bashashati M, Ahmadi M, Hojjati
34 35	18	M. Surgical approach to vascular complications of intravenous drug abuse. Eur J Vasc
36 37	19	Endovasc Surg 2006 Oct;32(4):397-401.
38	20	29. Naqi SA, Khan HM, Akhtar S, Shah TA. Femoral pseudoaneurysm in drug addicts
40	21	excision without revascularization is a viable option. Eur J Vasc Endovasc Surg 2006
41 42	22	Jun;31(6):585-7.
43 44 45 46 47 48 49 50 51	23	30. Al Shakarchi J, Wall M, Garnham A, Hobbs S, Newman J. Artery Ligation for Infected
	24	Femoral Pseudoaneurysms Does Carry a High Risk of Major Amputation. Ann Vasc
	25	Surg 2019 Jul;58:326-330.
	26	31. Rayyan. Rayyan Intelligent Systematic Review. https://www. rayyan.ai/ (accessed 5
	27	September 2022).
52 53	28	32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews
54 55	29	and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
56 57	30	33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of
58 59	31	Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,
60	32	2011. Available from http://handbook.cochrane.org.

2		
3 4	1	34. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
5	2	Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
7	3	meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
8 9	4	35. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M,
10 11	5	Aromataris E. Methodological quality of case series studies: an introduction to the
12 13	6	JBI critical appraisal tool. JBI Evidence Synthesis 2020;18(10):2127-2133.
14	7	36. Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, Morton SC,
15 16 17	8	Viswanathan M, Bass EB, Butler M, Gartlehener G, Hartley L, McPheteers M, Morgan
17 18	9	LC, Reston J, Sista P, Whitlock E, Chang S. Grading the strength of a body of evidence
19 20	10	when assessing health care interventions: an EPC update. J Clin Epidemiol
21 22	11	2015;68:1312e1324.
23 24	12	37. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
25	13	review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
26 27 28	14	<i>BMJ</i> 2015;349:g7647.
28 29	15	38. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
30 31	16	review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
32 33		
34 35	17	
36 37	18	
38	19	
39 40	20	
41 42	21	
43 44	22	
45 46	23	
47	24	
40	25	
50 51	26	
52 53	27	
54 55	28	
56 57	29	
58 50	30	
60	31	

("Intrav\* drug use\*" OR "Intrav\* drug abuse\*" OR "Intrav\* drug misuse\*" OR "Intrav\* drug addict\*" OR "Drug use\*" OR "Drug abuse\*" OR "Drug misuse\*" OR "Drug addict\*" OR "Substance use\*" OR "Substance abuse\*" OR "Substance misuse\*" OR Inject\* adj3 drug\*)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

("Femoral\*" OR "Groin") AND

("Pseudoan\*" OR "Pseudo-an" OR "False an\*")

Search Strategy for EMBASE, MEDLINE and Scopus

Appendix 1

AND

**Supplementary Material** 

			BMJ Open g j
			opyr Yr
			ight.
			-070
Appendix 2			line 615
PRISMA-P (Prefer	red Re	norting l	යි ඉ tems for Systematic review and Meta-Analysis Protocols) 2015 checkbst: recommended items to address in
a systematic revie	ew pro	tocol*	
Section and topic	Item	Page No	Checklist item
	No	i uge no	
ADMINISTRATIVE IN	FORMA	TION	ed to Do
Title:	-	-	tey Strategy
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration
Authors:			
Contact	За	1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide provi
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review 🗧 💈
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protection is the protocol and list changes; otherwise, state plan for documenting important protocol amendments
Support:			anc
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing th라profecol
INTRODUCTION			
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known هو. المعنى
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
			iphique d
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Information sources98Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or of literature sources) with planned dates of coverageSearch strategy1016Present draft of search strategy to be used for at least one electronic database, including of planned limits, such that it co repeatedStudy records:Data11a8-10Describe the mechanism(s) that will be used to manage records and data throughout strategy for the second strategy and the second strategy is through each phase of the processData11b8-10Describe the mechanism(s) that will be used for selecting studies (such as two independent regimes)Selection11b8-10Describe planned method of extracting data from reports (such as piloting forms, doing the processData collection11c8-10Describe planned method of extracting data from reports (such as PICO items, funding and confirming data from investigatorsData items129List and define all variables for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesisOutcomes and138,10List and define all outcomes for assessing risk of bias of individual studies, including methet this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe anticipated methods for assessing risk of bias of individual studies, including methet will be done at the c combining data from studies, including any planned exploration of consistency (such as propriate or combining data from the synthesis, describe planned sum	Information sources         9         8         Describe all intended information sources (such as electronic databases, contact with study, authors, trial registers on literature sources) with planned dates of coverage           Search strategy         10         16         Present draft of search strategy to be used for at least one electronic databases, including planned limits, such that it repeated           Study records:         Data         11a         8-10         Describe the mechanism(s) that will be used for selecting studies (such as two independent reduptions of the second state the process that will be used for selecting studies (such as ploting forms, den ging ependent v, in duplicate), process         11b         8-10         Describe planned method of extracting data from reports (such as ploting forms, den ging ependently, in duplicate), process           Data titems         12         9         Ust and define all variables for which data will be sought, including prioritisation of the second strategy and soft state how this information will be used individual studies, including widther this will be done at the advise of the study level, or bots; state how this information will be used in data synthesis         13a         8,10         Ust and define all outcomes for which data will be sought, including prioritisation of the second strategy and additional outcomes, the individual studies, including widther this will be done at the individual studies.         13a         8,10         Describe anticipated methods for assessing risk of bias of individual studies, including widther this will be done at the individual studies.         15a         10         Describe any propose			BMJ Open by ja. cg be
Information sources98Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or of literature sources) with planned dates of coverageSearch strategy1016Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it co repeatedStudy records: 	Information sources       9       8       Describe all intended information sources (such as electronic databases, contact wind stady authors, trial registers on literature sources) with planned dates of coverage         Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it repeated         Study records:			-2022-01 yright, ir
Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it correpeated         Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout graph between the mechanism strategy to be used for selecting studies (such as two independent records);       In the mechanism strategy         Selection       11b       8-10       State the process that will be used for selecting studies (such as two independent records);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting for obtaining and confirming data from investigators       Intervention of the mechanism strategy to be used for which data will be sought, including prioritisation of the mechanism study level, or both; state how this information will be used in data synthesis       Intervention of the mechanism study level, or both; state how this information will be used in data synthesis       Intervention of the mechanism study level, or both; state how this information will be used in data synthesis of the used study level, or both; state how this information will be used in data synthesis of the used study	Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it repeated         Study records:	iformation sources	9 8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other gre literature sources) with planned dates of coverage
Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout the process that will be used for selecting studies (such as two independent records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       Image: State the process that will be used for selecting studies (such as two independent records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       Image: State the process that will be used for selecting studies (such as piloting forms, down of the process of the process of the obtaining and confirming data from investigators of obtaining and confirming data from investigators of obtaining and simplifications       Image: State the process of the proceses of the process of the proces of the process of the p	Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       The process of that is, screening, eligibility and inclusion in meta-analysis)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as two independent reports)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, domethod perces), any pre-planned data and simplifications         Data items       12       9       List and define all outcomes for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesis         Outcomes and       13       8,10       List and define all outcomes for which data will be used in data synthesis         Tisk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including with the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measeres, the thods of handling data ar combining data from studies, including any planned exploration of consistency (suchas as tudies) for insudies, including any planned asesestive for on	earch strategy	10 16	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Data management11a8-10Describe the mechanism(s) that will be used to manage records and data throughout is be eview managementSelection process11b8-10State the process that will be used for selecting studies (such as two independent retrieves) through each phase of the (that is, screening, eligibility and inclusion in meta-analysis)Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, domesing for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding forms, domesing and simplificationsOutcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of 	Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout be been with the process of that is, screening, eligibility and inclusion in meta-analysis)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, dome of the process for obtaining and confirming data from investigators for obtaining and confirming data from investigators       Image: script of the planned method of extracting data from investigators for obtaining former, and simplifications         Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding formerces), any pre-planned data and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the script of the s	tudy records:		Se a
Selection process11b8-10State the process that will be used for selecting studies (such as two independent rewers) through each phase of the (that is, screening, eligibility and inclusion in meta-analysis)Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, dometication, an for obtaining and confirming data from investigatorsand simplification), an for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding beam ces), any pre-planned data as and simplificationsOutcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned expl	Selection       11b       8-10       State the process that will be used for selecting studies (such as two independent redefined in the second process of the second proces of the second process of the second proces of the secon	Data 1 management	11a 8-10	Describe the mechanism(s) that will be used to manage records and data throughout the beview
Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, do fighe pendently, in duplicate), an for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding and simplificationsOutcomes and 	Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, do fight dependently, in duplicate), for obtaining and confirming data from investigators         Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding storces), any pre-planned dat. and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesis       10         Risk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be quantitatively synthesised       10         15b       10       Describe criteria under which study data will be quantitatively synthesised       10         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)       15c         15d       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within se	Selection 1 process	11b 8-10	State the process that will be used for selecting studies (such as two independent red awars) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data items129List and define all variables for which data will be sought (such as PICO items, funding both ces), any pre-planned data and simplificationsOutcomes and138,10List and define all outcomes for which data will be sought, including prioritisation of the prioritizationRisk of bias in1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesis15Data synthesis15a10Describe criteria under which study data will be quantitatively synthesised combining data from studies, including any planned exploration of consistency (such as IC Kendall's τ)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses meteregression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding burgers), any pre-planned data and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the sought and additional outcomes, prioritization         Risk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the individual studies         Data synthesis       15a       10       Describe criteria under which study data will be guantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data ar combining data from studies, including any planned exploration of consistency (such as general-regression)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses general-regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADEF         * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group Profesere	Data collection 1 process	11c 8-10	Describe planned method of extracting data from reports (such as piloting forms, do sind be pendently, in duplicate), any proce for obtaining and confirming data from investigators
Outcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of to be sought, including prioritisation of to be sought, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisRisk of bias in individual studies1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, aethods of handling data and 	Outcomes and prioritization       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the fibe of the sought, including prioritisation of the sought, including whether this will be done at the individual studies         Risk of bias in individual studies       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, nethods of handling data are combining data from studies, including any planned exploration of consistency (suclease for end the synthesis is not appropriate, describe the type of summary planned         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses methor regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         0       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         0       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         0       If stributed under a Creative Commons Attribution Licence 4.0.	ata items	12 9	List and define all variables for which data will be sought (such as PICO items, funding for the sources), any pre-planned data assumption and simplifications
Risk of bias in1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the original studiesIndividual studiesstudy level, or both; state how this information will be used in data synthesisImage: Study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as sensitivity or subgroup analyses meta-regression)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Risk of bias in individual studies       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, arethods of handling data are combining data from studies, including any planned exploration of consistency (success is Kendall's τ)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses smeeter regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within s         Confidence in 17       10       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         evidence       *       It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Green attributed under a Creative Commons Attribution Licence 4.0.         Fram: Shameser L. Moher D. Clarke M. Cherci D. Liberati A. Battigr	utcomes and rioritization	13 8,10	List and define all outcomes for which data will be sought, including prioritisation of the and additional outcomes, with ration
Data synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as log Kendall's τ)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses geneta-regression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised       is	isk of bias in ndividual studies	14 10	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcom study level, or both; state how this information will be used in data synthesis
<ul> <li>15 10 If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as the Kendall's τ)</li> <li>15c 10 Describe any proposed additional analyses (such as sensitivity or subgroup analyses general-regression)</li> <li>15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned</li> </ul>	15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data are combining data from studies, including any planned exploration of consistency (such as is Kendall's τ)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses geneth-regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         veidence       15       10       Describe read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Greater a Creative Commons Attribution Licence 4.0.         From:       Shamesaer L. Moher D. Clarko M. Charsi D. Libergti A. Patticraw M. Shakalla B. Stewart L. DBIGMA B. Creater D. Stewart L.	ata synthesis	15a 10	Describe criteria under which study data will be quantitatively synthesised
15c 10 Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression) 15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned and service of service of service of summary planned and service of	15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses methods)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies) selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         evidence       15       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Greater is the strength of Licence 4.0.         From:       Shamcaar I. Moher D. Clarka M. Charci D. Liberati A. Patticrony M. Shekalla B. Stawart I. DBISMA B. Group. Proferred expecting in temp for expecting with sheares in analysis.	1	15b 10	If data are appropriate for quantitative synthesis, describe planned summary meas 🛱 es, 💑 ethods of handling data and methoc combining data from studies, including any planned exploration of consistency (such as is Kendall's τ)
15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned 🚊 S	15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across stuclies selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         cumulative	1	15c 10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)
	Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition bias across studies selective reporting within second condition bias across studies across studies selective reporting within second condition condition bias across studies across studies selective reporting within second condition condition bias across studies across studies across studies selective reporting within second condition condition bias across studies across	1	15d N/A	If quantitative synthesis is not appropriate, describe the type of summary planned 🚆 🦉
Meta-bias(es) 16 N/A Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within stud	Confidence in 17 10 Describe how the strength of the body of evidence will be assessed (such as GRADE) cumulative evidence * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Gr distributed under a Creative Commons Attribution Licence 4.0.	/leta-bias(es)	16 N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies
Confidence in 17 10 Describe how the strength of the body of evidence will be assessed (such as GRADE) cumulative evidence	* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for importan on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Go distributed under a Creative Commons Attribution Licence 4.0.	onfidence in umulative vidence	17 10	Describe how the strength of the body of evidence will be assessed (such as GRADE) 2



a systematic revie	ew pro	otocol*	
Section and topic	ltem No	Page No	Checklist item ទី ភី ឆ្លូ ក្នុ
ADMINISTRATIVE INI	ORMA	TION	is reig
Title:			ateo
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration မြာမြို့နိုင်ငံ
Authors:			
Contact	3a	1	Provide name, institutional affiliation, e-mail address of all protocol authors; providog gical mailing address of correspondin author 프로머프
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review $\exists \mathfrak{S}$
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:			aini
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION			ar te
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known 💙 💈 📑
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to barticipants, interventions, compar and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and rerent to characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9	8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other gr literature sources) with planned dates of coverage

Page 21 of 23

3 4

34

44 45

			BMJ Open g g
			opyri
			ght, ir
Search strategy	10	16	Present draft of search strategy to be used for at least one electronic database, including lanned limits, such that it could be repeated
Study records:			
Data management	11a	8-10	Describe the mechanism(s) that will be used to manage records and data throughou the review
Selection process	11b	8-10	State the process that will be used for selecting studies (such as two independent rexiews) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c	8-10	Describe planned method of extracting data from reports (such as piloting forms, do a planned method of extracting data from reports (such as piloting forms, do a planned method of extracting data from investigators
Data items	12	9	List and define all variables for which data will be sought (such as PICO items, funding s ces), any pre-planned data assumptions and simplifications
Outcomes and prioritization	13	8,10	List and define all outcomes for which data will be sought, including prioritisation of a finand additional outcomes, with rationale
Risk of bias in individual studies	14	10	Describe anticipated methods for assessing risk of bias of individual studies, including wither this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	15a	10	Describe criteria under which study data will be quantitatively synthesised 🛛 🛓 🧕
	15b	10	If data are appropriate for quantitative synthesis, describe planned summary measures, whethods of handling data and methods of combining data from studies, including any planned exploration of consistency (such the subscripts subscripts subscripts subscripts).
	15c	10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses net a-regression)
	15d	N/A	If quantitative synthesis is not appropriate, describe the type of summary planned 👸 🔓
Meta-bias(es)	16	N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within studies)
Confidence in cumulative evidence	17	10	Describe how the strength of the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence will be assessed (such as GRADE) is the body of evidence w
* It is strongly recom on the items. Amend distributed under a C From: Shamseer L, Ma analysis protocols (PE	mended ments t creative oher D, (	I that this to a review Common Clarke M,	s checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification w protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is a Attribution Licence 4.0.
		, 2013, 21	Bibliographique d



# **BMJ Open**

## The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting Drug Use and Outcomes: A Systematic Review Protocol

Journal:	BMJ Open
Manuscript ID	bmjopen-2022-070615.R2
Article Type:	Protocol
Date Submitted by the Author:	21-May-2023
Complete List of Authors:	MacLeod, Caitlin; NHS Tayside, Department of Vascular Surgery; University of Dundee, School of Medicine Strachan, David; NHS Tayside, Department of Vascular Surgery Radley, Andrew; University of Dundee, School of Medicine; NHS Tayside, Directorate of Public Health Khan, Faisel ; University of Dundee, School of Medicine Nagy, John; NHS Tayside, Department of Vascular Surgery Suttie, Stuart; NHS Tayside, Department of Vascular Surgery
<b>Primary Subject Heading</b> :	Surgery
Secondary Subject Heading:	Addiction, Cardiovascular medicine, Public health, Infectious diseases, Global health
Keywords:	Vascular surgery < SURGERY, VASCULAR SURGERY, Substance misuse < PSYCHIATRY, PUBLIC HEALTH, Surgical pathology < PATHOLOGY

SCHOLARONE<sup>™</sup> Manuscripts Page 1 of 23

1

2		
4	1	The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting
5 6	2	Drug Use and Outcomes: A Systematic Review Protocol
7	3	
8 9	4	CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee and School of Medicine,
10 11 12 13 14 15 16 17 18 19 20 21	5	University of Dundee, Dundee, Scotland, UK (ORCID 0000-0002-3839-352X)
	6	D Strachan, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK
	7	A Radley Public Health Directorate, Kings Cross Hospital, Dundee and School of Medicine, University
	8	of Dundee, Dundee, Scotland, UK (ORCID 0000-0003-4772-2388)
	9	F Khan, Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, Scotland,
	10	UK
	11	J Nagy, Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK
22	12	SA Suttie Department of Vascular Surgery, Ninewells Hospital, Dundee, Scotland, UK
23	13	
25 26 27 28	14	
	15	Corresponding Author
29 30	16	CS MacLeod, Department of Vascular Surgery, Ninewells Hospital, Dundee (ORCID - ORCID 0000-
31	17	0002-3839-352X)
32 33	18	<u>caitlin.macleod2@nhs.scot</u> (main email address)
34 35	19	090001033@dundee.ac.uk
36 37	20	
38 39 40 41 42 43	21	
	22	Key Words: Drug use; Vascular surgery; Infected arterial pseudoaneurysm; Health outcomes
	23	
43 44	24	Word count: 2462
45 46	25	
47 49		
48 49		
50 51		
52		
53 54		
55 56		
57		
58 59		
60		

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

The Management of the Infected Arterial Pseudoaneurysm Secondary to Groin Injecting **Drug Use and Outcomes: A Systematic Review Protocol** 

Abstract

Introduction

People who inject drugs (PWID) are at risk of a range of injecting-related infections and injuries, which can threaten life and limb. In parallel to escalating rates of drug-related deaths seen in Scotland and the UK, there has also been an increase in hospital admissions for skin and soft tissue infections related to injecting drug use. One such injecting complication is the infected arterial pseudoaneurysm, which risks rupture and life-threatening haemorrhage. Surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use remain contentious, with some advocates for ligation and debridement alone, whilst others promote acute arterial reconstruction (suture or patch repair, bypass or, more recently, endovascular stent-graft placement). Rates of major lower limb amputations related to surgical management for this pathology vary in the literature. This review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including open and endovascular options, for the infected arterial pseudoaneurysm secondary to groin injecting drug use.

Methods and Analysis

The methods will follow the Preferred Reporting Items for Systematic reviews and Meta-Analysis checklist. Three electronic databases will be searched and the resultant papers screened according to the study inclusion and exclusion criteria (detailed in the Population, Intervention, Comparison, Outcomes and Study design statement). Grey literature will be excluded. All papers at each stage will be screened by two independent authors, with disagreements arbitrated by a third. Papers will be subject to appropriate standardised quality assessments. Primary outcome: major lower limb amputation. Secondary outcomes: re-intervention rate; re-bleeding rate; development of chronic limb-threatening ischaemia 30-day mortality and claudication.

2		
3 4	1	Ethics and Dissemination
5	2	This is a systematic review based upon previously conducted studies, therefore no ethical
7	3	approval is required. The results of this work will be published in a peer-reviewed journal and
8 9	4	presented at relevant conferences.
10 11	5	
12	6	PROSPERO Registration Number: CRD42022358209
14	7	
15 16	8	Strengths and Limitations of This Study
17 18	9	
19 20	10	• The study design comprises a comprehensive search strategy and selection criteria.
21	11	with double-screening of all studies to reduce selection bias and data collection errors.
22 23	12	The inclusion of primary endoyascular stept-graft placement as a treatment modality
24 25	12	for this nothology
26 27	14	The use of propertional mate analysis to entimize inclusive incorporation of outcomes
28	14	The use of proportional meta-analysis to optimise inclusive incorporation of outcomes
29 30	15	from non-comparator studies in quantitative analysis.
31 32	16	<ul> <li>Limitations of the study are excluding non-English language papers and grey literature.</li> </ul>
33		
34 35		
36		
37 38		
39		
40		
41 42		
43		
44		
45		
40 47		
48		
49		
50		
51		
52		
53 54		
54 55		
56		
57		
58		
59		
60		

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

## 

#### Introduction

In recent years drug-related deaths have been rising across countries such as the United Kingdom, most markedly in Scotland, and the United States, reflecting increases in drugrelated harms.<sup>1-3</sup> In parallel to these drug deaths there has also been an observed increase in hospital admissions for skin and soft tissue infections related to injecting drug use.<sup>4,5</sup> People who inject drugs (PWID) are at risk of range of injecting-related infections and injuries, some of which may threaten life and limb.<sup>6,7</sup>

One such injecting injury is the infected arterial pseudoaneurysm. A pseudoaneurysm (or false aneurysm) represents a defect in the arterial wall with haemorrhage contained by the surrounding soft tissues, compressed thrombus and not lined by endothelium.<sup>8</sup> It is distinct from a true aneurysm, which involves dilatation of the arterial wall. Continued extravasation and expansion of a pseudoaneurysm ultimately risks free rupture.<sup>9</sup> The arterial wall in PWID can also be further compromised by the severity of surrounding infection present, as well as the caustic acidifying agents injected.<sup>9-12</sup> 

A pseudoaneurysm is the most commonly described arterial complication of injecting drug use. In the context of PWID, they can develop from direct, typically infective, trauma to an artery, usually when attempting to inject intravenously, or during intentional arterial injecting. Given the probable non-sterile injecting technique, this can lead to the formation of an intramural abscess/haematoma complex.<sup>8,9,13,14</sup> Arterial pseudoaneurysms may also occur as a result of malignant local infective invasion with destruction of arterial integrity from perivascular soft tissue sepsis.<sup>9,10,12,13</sup> A further aetiology is septic metastases, for example from infective endocarditis.<sup>10,14</sup> Arterial pseudoaneurysms in the groin are the most frequently reported in PWID resultant from injecting into this anatomical region. However arterial pseudoaneurysms may occur anywhere throughout the arterial vasculature, usually where injecting has been undertaken.<sup>13,14</sup> If untreated they may rupture causing catastrophic, life-threatening haemorrhage.

Management options for arterial pseudoaneurysms secondary to injecting drug use remain contentious.<sup>10,13-15</sup> The options for initial operative management include: arterial ligation and 

Page 5 of 23

### **BMJ** Open

debridement alone or arterial reconstruction with debridement.<sup>10,13,14,16</sup> Arterial reconstruction comprises primary repair of the defect with a suture or patch repair, or a bypass of the ligated pseudoaneurysm to compensate for the reduced distal blood supply.<sup>10,13,14,17,18</sup> Such bypasses can be routed either extra-anatomically (circumventing the infected field) or anatomically (in-situ). More recently endovascular reconstructions with stent-grafts have also been reported.<sup>19,20</sup>

However, reticence exists regarding arterial reconstruction due to the degree of pathogenic contamination common to these cases, which can risk infection of the reconstruction and predispose to life-threatening haemorrhage.<sup>15</sup> Autologous vein would usually be the preferred conduit for reconstruction, especially in an infected field, although this is often not available in PWID due to venous damage and destruction from injecting.<sup>15,18</sup> Use of the internal iliac artery as an autologous conduit has also been described.<sup>18</sup> Prosthetic grafts are high risk for infection, particularly in this setting. Biosynthetic and biologic (encompassing cadaveric) conduits are alternatives, but also risk infection.<sup>20-22</sup> An additional concern is continued injecting, introduction of further infection and also use of any reconstruction for drug-using vascular access.<sup>15,23</sup> Moreover, arterial reconstruction may not be required due to adequate residual perfusion of the limb post-ligation, and thus may pose more risk to the patient.<sup>15,16</sup> Rates of major lower limb amputation following ligation vary in the literature from 0% to 3.3% to 33%.<sup>16,24-30</sup> The purpose of this systematic review is to analyse published specific outcomes, following the different surgical management options for the infected arterial pseudoaneurysm secondary to groin injecting drug use. The timing of interest for these management options is immediate (at the index procedure) or during the acute admission episode (non-immediate). To our knowledge this is the first systematic review on this topic to incorporate endovascular reconstructions in addition to open management.

27 Objectives

This systematic review aims to evaluate the outcomes of arterial ligation alone compared to arterial reconstruction, including endovascular management, for the infected arterial pseudoaneurysm secondary to groin injecting drug use. Arterial reconstructions of interest will be those performed at the index operation and during the acute admission episode for

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

**BMJ** Open

this pathology. The primary outcome will be major lower limb amputation. Secondary
outcomes will be re-intervention rate, re-bleeding rate, development of chronic limbthreatening ischaemia (CLTI), 30-day mortality and claudication.

Methods and Analysis

This systematic review will include all studies that meet the Population, Intervention, Comparison, Outcomes and Study design (PICOS) statement (Table 1) and eligibility criteria.

Table 1. PICOS Statement.

Population	Adults (aged $\geq$ 18 years) with an infected arterial pseudoaneurysm
	secondary to grain injecting drug use (this may involve the common
	secondary to grow injecting drug use (this may involve the common
	femoral, superficial femoral, profunda femoris, external iliac or
	common iliac arteries)
Intervention	Arterial reconstruction by way of repair (suture or patch repair),
	bypass operation (if ligation performed) or endovascular stent-graft
	placement +/- debridement and undertaken immediately (at the index
	surgical intervention) or during the acute admission episode
Comparison	Ligation of the infected arterial pseudoaneurysm +/- debridement
	alone at index surgical intervention
Outcomes	Primary outcome: Major lower limb amputation
	Secondary outcomes: Re-intervention rate; re-bleeding rate;
	development of chronic limb-threatening ischaemia (CLTI); 30-day
	mortality and claudication
Study Design	Randomised controlled trials, prospective and retrospective
	observational cohort studies and case series (four or more patients)

## 1 Eligibility criteria

The search will be performed in relevant electronic databases. Only full published papers in English will be included. The grey literature, encompassing conference abstracts, will be excluded. The anatomical location of the pseudoaneurysm, the corresponding intervention executed and related outcomes must be reported clearly in the paper or else it will be excluded (*i.e.* if the management and outcomes of pseudoaneurysms in different anatomical locations are described cumulatively along with each intervention and outcome, rendering those specifically related to the groin indistinguishable). Papers that detail only some of the outcomes of interest, however distinctly report the related management method for the correct anatomical area will be included with documentation of the outcomes reported on, and "Not reported" or "Unclear" as applicable.

14 Population

29 15

The population of interest are PWID who have developed infected arterial pseudoaneurysms secondary to groin injecting drug use (*i.e.* infected arterial pseudoaneurysms related to the groin, typically due to injecting drug use in this anatomical region, and can involve the following vasculature: the common femoral, superficial femoral, profunda femoris, external iliac or common iliac arteries). The case definition will be any arterial pseudoaneurysm secondary to groin injecting drug use. Cases will be ascertained on radiological findings (if imaging performed) and clinically, including at the time of operation. All arterial pseudoaneurysms in this review will be considered infected due to the aetiology. Non-sterile injecting predominantly precipitates the ensuing pathophysiology in these cases, which is typically infective rather than simply traumatic.<sup>9</sup> PWID are defined as individuals who inject drugs, which may be illicit or prescribed, with the latter not being used in conduct with the prescription e.g. injection of methadone or crushed tablets in solution originally intended for oral consumption. 

1	Interventions
-	miller ventions

The intervention consists of any arterial reconstruction undertaken to surgically manage an infected arterial pseudoaneurysm secondary to groin injecting drug use. This may be a suture or patch repair (the patch material may be autologous, prosthetic, biosynthetic or biologic). It also includes a bypass operation to compensate for arterial ligation of an infected arterial pseudoaneurysm (this may be performed prior to the ligation at the index intervention through an extra-anatomical route in an attempt to try and limit contamination of the reconstruction). The bypass operation may be routed extra-anatomically or anatomically and the conduit may be autologous, prosthetic, biosynthetic or biologic. Endovascular management through placement of a stent-graft across anatomically suitable pseudoaneurysms will also be incorporated into the review. Comparison Arterial ligation alone with no arterial reconstruction will be considered to be the comparator. Outcomes The studies should report on the primary outcome: major lower limb amputation. Secondary outcomes of interest are: re-intervention rate; re-bleeding rate; development of CLTI, 30-day mortality and claudication. Study design Primary studies, which may be prospective or retrospective, in English will be included. There will be no restrictions to geographical location of the study. Patient and public involvement There was no direct patient and public participation in this study as it is a protocol for a systematic review.

1 2		
3 4	1	Information sources and search strategy
5	2	
7	3	The electronic databases to be systematically searched are: EMBASE; MEDLINE and Scopus.
8 9	4	There will be no time restriction to the search (running from 1974 to search date in EMBASE,
10 11	5	1946 in MEDLINE and 1960 in Scopus). The search strategy was devised to fulfil the PICOS
12 13	6	statement and employed free search terms (search strategy for each database detailed in the
14 15	7	Supplementary Material, Appendix 1). Papers produced from the search will be limited to the
16	8	English language and any grey literature identified will be excluded. Authors of recent
18	9	publications may be contacted for missing data.
19 20	10	
21 22	11	Data
23 24	12	
25 26	13	Data selection and coding
27	14	
29	15	All studies resultant from the search will be exported to EndNote 20 (Clarivate) and duplicates
30 31	16	removed. These studies will then be transferred to Rayyan, a web-based platform to facilitate
32 33	17	collaborative systematic literature review screening. <sup>31</sup> Titles and abstracts will be
34 35	18	independently screened by two authors (CSM and DS) in accordance with the selection
36 37	19	criteria. Any differences during the screening process will be arbitrated by a third author
38 39	20	(JN/SAS/AR) in order to reach a final decision.
40	21	
41 42	22	The study selection process will be recorded in a Preferred Reporting Items for Systematic
43 44	23	reviews and Meta-Analysis (PRISMA) flow diagram. <sup>32</sup> The papers from the title and abstract
45 46	24	screening will be then be subject to the PICOS criteria, with those not meeting these elements
47 48	25	excluded and the reason recorded.
49 50	26	
50 51	27	Data extraction
52 53	28	
54 55	29	Data will be extracted from all studies that meet the inclusion criteria and it will be
56 57	30	undertaken independently by two authors (CSM and DS). Any disagreements in extraction will
58 59	31	be reviewed and decided upon by a third author (JN/SAS/AR). Data to be extracted are: study
60	32	design; population size and basic demographics (age, gender); anatomical location of the

Enseignement Superieur (ABES) . Protected by copyright, including for uses related to text and data mining, Al training, and similar technologies.

arterial pseudoaneurysm; presentation with rupture; surgical intervention details (ligation
and number of arteries ligated and information on reconstruction if performed); major lower
limb amputation; need for further intervention; re-bleeding rate; development of CLTI; 30day mortality; claudication; wound management; wound complications and follow-up
duration. For the arterial reconstructions, graft infections and thromboses will also be
recorded. If reported, the clinical status of the patient at presentation and influence of this
on management will also be documented.

9 Risk of bias (quality) assessment

11 The appropriate assessment tool will be used for the design of each study included: the 12 Cochrane Collaboration's risk of bias tool for randomised studies (randomised controlled 13 trials), the Newcastle-Ottawa Scale for cohort studies and the Joanna Briggs Institute critical 14 appraisal tool for case series.<sup>33-35</sup> Evaluation using these tools will again be performed 15 independently by two authors (CSM and DS). Divergences in scoring will be settled by a third 16 author (AR/JN/SAS).

N.C

18 Synthesis and Analysis

Data to be quantitatively synthesised are: major lower limb amputation rate; re-intervention rate; re-bleeding rate; development of CLTI, 30-day mortality and claudication. Data for each outcome will be quantitatively pooled and assessed using suitable statistical tools and models (i.e. proportional and conventional comparative meta-analyses). The robustness of the resultant evidence will be subject to Grading of Recommendations, Assessment, Development and Evaluations (GRADE) framework by two authors (CSM and DS), with any differences reviewed by a third author (AR/JN/SAS).<sup>36</sup> Heterogeneity will also be assessed using an appropriate statistical tool when the number of identified studies and the amount of variation between trials can be defined. If the data allows, there will also be subgroup analyses of ligation and debridement alone, compared to open and endovascular reconstructions respectively. 

2		
3 4	1	This systematic review protocol has also been written in accordance with the PRISMA-P
5 6	2	checklist (Supplementary Material, Appendix 2). <sup>37,38</sup>
7	3	
8 9	4	Potential Implications
10 11	5	
12 13	6	There is no current consensus on the surgical management of the infected arterial
14 15	7	pseudoaneurysm secondary to groin injecting drug use. This review aims to give a
16 17	8	comprehensive and contemporary overview of the literature and relevant outcomes to aid in
18	9	informing practice.
20	10	
21 22	11	Ethics and Dissemination
23 24	12	
25 26	13	This systematic review will involve studies which have been performed and so ethical
27	14	approval is not required. The review has been registered on PROSPERO and the final results
20 29 20	15	will be submitted to a peer-reviewed journal, as well as presented at relevant conferences.
30 31	16	Any adjustments to the study protocol will be recorded on PROSPERO.
32 33	17	
34 35	18	Review Status
36 37	19	
38	20	The systematic search of the electronic databases has been undertaken, and the screening of
40	21	the study titles and abstracts is underway. The review detailed in this protocol is planned to
41 42	22	be completed in January 2023, with the report written in April 2023.
43 44	23	
45 46	24	Funding
47 48	25	
49 50	26	No funding has been received for this study.
50 51	27	
52 53	28	Competing Interest
54 55	29	
56 57	30	None.
58 59	31	
60	32	

Protected by copyright, including for uses related to text	Enseignement Su
data mining,	ur (ABES)
, AI training, and similar technologies.	

1	Patient Consent for Publication
2	
3	Not applicable.
4	
5	Ethical Approval
6	
7	This study does not involve human participants.
8	
9	Provenance and Peer Review
10	
11	Not commissioned, externally peer-reviewed.
12	
13	Data Sharing
14	
15	Raw data generated from this systematic review will be shared upon request.
16	
17	Acknowledgements
18	
19	We thank Scott McGregor at the University of Dundee library for advice and comments on
20	the search strategy.
21	
22	Author Contributions
23	
24	CSM has devised the plan for the systematic review, written the protocol, performed the
25	initial searches and will undertake the data collection, quality assessment and will draft the
26	systematic review paper. DS will contribute to independent data collection and quality
27	assessments of the included papers. AR has contributed to the design of the systematic
28	review and will guide study quality assessments and heterogeneity analyses. FK, JN and SAS
29	have also contributed to the design of the systematic review. JN, SAS and AR will also arbitrate
30	in differences between the independently assessing authors, CSM and DS. All authors have
31	contributed to reviewing this protocol and will contribute to the final systematic review

manuscript. CSM is the guarantor of the review.

2		
4	1	References
5 6	2	
7 8	3	1. Office for National Statistics. Deaths related to drug poisoning in England and Wales:
9	4	2021 Registrations. London: Office for National Statistics, Aug 2022.
10 11	5	2. National Records of Scotland. Drug Related Deaths in Scotland in 2021. Edinburgh:
12 13	6	National Records of Scotland, Jul 2022.
14 15	7	3. Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid
16 17	8	overdose crisis. Curr Opin Psychiatry. 2021 Jul 1;34(4):344-350.
18	9	4. Lewer D, Harris M, Hope V. Opiate Injection-Associated Skin, Soft Tissue, and
19 20	10	Vascular Infections, England, UK, 1997-2016. Emerg Infect Dis 2017 Aug;23(8):1400-
21 22	11	1403.
23 24	12	5. Ciccarone D, Unick GJ, Cohen JK, Mars SG, Rosenblum D. Nationwide increase in
25 26	13	hospitalizations for heroin-related soft tissue infections: Associations with structural
27 20	14	market conditions. Drug Alcohol Depend 2016 Jun 1;163:126-33.
20 29	15	6. MacLeod CS, Senior Y, Lim J, Mittapalli D, Guthrie GJK, Suttie SA. The Needle and the
30 31	16	Damage Done: A retrospective review of the health impact of recreational
32 33	17	intravenous drug use and the collateral consequences for Vascular Surgery. Ann Vasc
34 35	18	Surg 2022 Jan;78:103-111.
36 37	19	7. Larney S, Peacock A, Mathers BM, Hickman M, Degenhardt L. A systematic review of
38 39	20	injecting-related injury and disease among people who inject drugs. Drug Alcohol
40 41	21	Depend 2017 Feb 1;171:39-49.
42	22	8. Cronenwett JL, Gloviczki P, Johnston KW, Kempczinski RF, Krupski WC. Rutherford's
43 44	23	Vascular Surgery 2-volume set (5 <sup>th</sup> Edition). London, UK: WB Saunders Company;
45 46	24	2000.
47 48	25	9. Anderson CB, Butcher HR, Ballinger WF. Mycotic Aneurysms. Arch Surg 1974;
49 50	26	109(5):712-717.
51 52	27	10. Stevenson RP, Tolias C, Hussey K, Kingsmore DB. Mycotic pseudoaneurysm in
53	28	intravenous drug users: current insights. Research Reports in Clinical Cardiology
54 55	29	2019;10:1-6.
56 57	30	11. Ciccarone D, Harris M. Fire in the vein: heroin acidity and its proximal effect on
58 59 60	31	users' health. Int J Drug Policy 2015;26(11):1103–10.

Enseignement Superieur (ABES) Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.

BMJ Open

3 4	1	12. Harris M, Scott J, Wright T, Brathwaite R, Ciccarone D, Hope V. Injecting-related
5	2	health harms and overuse of acidifiers among people who inject heroin and crack
7	3	cocaine in London: a mixed-methods study. Harm Reduct J 2019 Nov 13;16(1):60.
8 9	4	13. Coughlin PA, Mavor AI. Arterial consequences of recreational drug use. Eur J Vasc
10 11	5	Endovasc Surg 2006 Oct;32(4):389-96.
12 13	6	14. Fiddes R, Khattab M, Abu Dakka M, Al-Khaffaf H. Patterns and management of
14 15	7	vascular injuries in intravenous drug users: a literature review. Surgeon 2010
16 17	8	Dec;8(6):353-61.
17	9	15. Welch GH, Reid DB, Pollock JG. Infected false aneurysms in the groin of intravenous
19 20	10	drug abusers. Br J Surg 1990 Mar;77(3):330-3.
21 22	11	16. Quiroga E, Shalhub S, Tran NT, Starnes BW, Singh N. Outcomes of femoral artery
23 24	12	ligation for treatment of infected femoral pseudoaneurysms due to drug injection. J
25 26	13	Vasc Surg 2021 Feb;73(2):635-640.
27 28	14	17. Padberg F Jr, Hobson R 2nd, Lee B, Anderson R, Manno J, Breitbart G, Swan K.
20	15	Femoral pseudoaneurysm from drugs of abuse: ligation or reconstruction? J Vasc
30 31	16	Surg 1992 Apr;15(4):642-8.
32 33	17	18. Klonaris C, Katsargyris A, Papapetrou A, Vourliotakis G, Tsiodras S, et al. Infected
34 35	18	femoral artery pseudoaneurysm in drug addicts: the beneficial use of the internal
36 37	19	iliac artery for arterial reconstruction. <i>J Vasc Surg</i> 2007 Mar;45(3):498-504.
38 39	20	19. Fu Q, Meng X, Li F, Wang X, Cheng J, et al. Stent-graft placement with early
40	21	debridement and antibiotic treatment for femoral pseudoaneurysms in intravenous
41	22	drug addicts. Cardiovasc Intervent Radiol 2015 Jun;38(3):565-72.
43 44	23	20. Bianchini Massoni C, Mariani E, De Troia A, Perini P, Nabulsi B, et al. Outcomes of
45 46	24	Surgical and Endovascular Treatment for Arterial Lesions in Intravenous Drug
47 48	25	Abusers. Ann Vasc Surg 2020 Nov;69:133-140.
49 50	26	21. Becker D, Béguin M, Weiss S, Wyss TR, Schmidli J, Makaloski V. In situ Reconstruction
51 52	27	of Infected Groin Pseudoaneurysms in Drug Abusers With Biological Grafts. Eur J
52	28	Vasc Endovasc Surg 2019 Oct;58(4):592-598.
54 55	29	22. Jayaraman S, Richardson D, Conrad M, Eichler C, Schecter W. Mycotic
56 57	30	pseudoaneurysms due to injection drug use: a ten-year experience. Ann Vasc Surg
58 59	31	2012 Aug;26(6):819-24.
60		

Page 15 of 23

1

2		
3 4	1	23. Georgiadis GS, Bessias NC, Pavlidis PM, Pomoni M, Batakis N, Lazarides MK. Infected
5 6	2	false aneurysms of the limbs secondary to chronic intravenous drug abuse: analysis
7 8	3	of perioperative considerations and operative outcomes. Surg Today
9	4	2007;37(10):837-44.
10 11	5	24. Mousavi SR, Saberi A, Tadayon N, Zeynalzadeh M, Kavyani A. Femoral artery ligation
12 13	6	as treatment for infected pseudo-aneurysms, secondary to drug injection. Acta Chir
14 15	7	<i>Belg</i> 2010 Mar-Apr;110(2):200-2.
16 17	8	25. Qiu J, Zhou W, Zhou W, Tang X, Yuan Q, <i>et al</i> . The Treatment of Infected Femoral
18	9	Artery Pseudoaneurysms Secondary to Drug Abuse: 11 Years of Experience at a
19 20	10	Single Institution. Ann Vasc Surg 2016 Oct;36:35-43.
21 22	11	26. DDin NU, Berlas FT, Rehman KU, Ali G, Salahuddin F, Mumtaz A. Outcomes of
23 24	12	Femoral Artery Pseudoaneurysm in Intravenous Drug Abusers Managed at a Tertiary
25 26	13	Care Center. <i>Cureus</i> 2021 Feb 15;13(2):e13350.
27	14	27. Gan JP, Leiberman DP, Pollock JG. Outcome after ligation of infected false femoral
29	15	aneurysms in intravenous drug abusers. Eur J Vasc Endovasc Surg 2000
30 31	16	Feb;19(2):158-61.
32 33	17	28. Yegane RA, Salehi NA, Ghaseminegad A, Bahrami F, Bashashati M, Ahmadi M, Hojjati
34 35	18	M. Surgical approach to vascular complications of intravenous drug abuse. Eur J Vasc
36 37	19	Endovasc Surg 2006 Oct;32(4):397-401.
38	20	29. Naqi SA, Khan HM, Akhtar S, Shah TA. Femoral pseudoaneurysm in drug addicts
40	21	excision without revascularization is a viable option. Eur J Vasc Endovasc Surg 2006
41 42	22	Jun;31(6):585-7.
43 44	23	30. Al Shakarchi J, Wall M, Garnham A, Hobbs S, Newman J. Artery Ligation for Infected
45 46	24	Femoral Pseudoaneurysms Does Carry a High Risk of Major Amputation. Ann Vasc
47 48	25	Surg 2019 Jul;58:326-330.
49	26	31. Rayyan. Rayyan Intelligent Systematic Review. https://www. rayyan.ai/ (accessed 5
51	27	September 2022).
52 53	28	32. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews
54 55	29	and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
56 57	30	33. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of
58 59	31	Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration,
60	32	2011. Available from http://handbook.cochrane.org.

2		
3 4	1	34. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The
5	2	Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in
7	3	meta-analyses http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
8 9	4	35. Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, Stephenson M,
10 11	5	Aromataris E. Methodological quality of case series studies: an introduction to the
12 13	6	JBI critical appraisal tool. JBI Evidence Synthesis 2020;18(10):2127-2133.
14	7	36. Berkman ND, Lohr KN, Ansari MT, Balk EM, Kane R, McDonagh M, Morton SC,
16	8	Viswanathan M, Bass EB, Butler M, Gartlehener G, Hartley L, McPheteers M, Morgan
17 18	9	LC, Reston J, Sista P, Whitlock E, Chang S. Grading the strength of a body of evidence
19 20	10	when assessing health care interventions: an EPC update. J Clin Epidemiol
21 22	11	2015;68:1312e1324.
23 24	12	37. Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic
25	13	review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
20	14	<i>BMJ</i> 2015;349:g7647.
28 29	15	38. Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic
30 31	16	review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
32 33		
34 35	17	
36 37	18	
38	19	
39 40	20	
41 42	21	
43 44	22	
45 46	23	
47	24	
40	25	
50 51	26	
52 53	27	
54 55	28	
56 57	29	
58 50	30	
60	31	

("Intrav\* drug use\*" OR "Intrav\* drug abuse\*" OR "Intrav\* drug misuse\*" OR "Intrav\* drug addict\*" OR "Drug use\*" OR "Drug abuse\*" OR "Drug misuse\*" OR "Drug addict\*" OR "Substance use\*" OR "Substance abuse\*" OR "Substance misuse\*" OR Inject\* adj3 drug\*)

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

("Femoral\*" OR "Groin") AND

("Pseudoan\*" OR "Pseudo-an" OR "False an\*")

Search Strategy for EMBASE, MEDLINE and Scopus

Appendix 1

AND

**Supplementary Material** 

			BMJ Open
			opyr Yr
			ight.
			-070
Appendix 2			line 615
PRISMA-P (Prefer	red Re	norting l	යි ඉ tems for Systematic review and Meta-Analysis Protocols) 2015 checkbst: recommended items to address in
a systematic revie	ew pro	tocol*	
Section and topic	Item	Page No	Checklist item
	No	i uge no	
ADMINISTRATIVE IN	FORMA	TION	ed to Do
Title:	_	-	tey Strategy
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration
Authors:			
Contact	За	1	Provide name, institutional affiliation, e-mail address of all protocol authors; provide provi
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review 🗧 💈
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protection is the protocol and list changes; otherwise, state plan for documenting important protocol amendments
Support:			anc
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing th라profecol
INTRODUCTION			
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known هو. المعنى
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
			iphique d
			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

Information sources98Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or of literature sources) with planned dates of coverageSearch strategy1016Present draft of search strategy to be used for at least one electronic database, including of planned limits, such that it co repeatedStudy records:Data11a8-10Describe the mechanism(s) that will be used to manage records and data throughout strategy for the second strategy and the second strategy is through each phase of the processData11b8-10Describe the mechanism(s) that will be used for selecting studies (such as two independent regimes)Selection11b8-10Describe planned method of extracting data from reports (such as piloting forms, doing the processData collection11c8-10Describe planned method of extracting data from reports (such as PICO items, funding and confirming data from investigatorsData items129List and define all variables for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesisOutcomes and138,10List and define all outcomes for assessing risk of bias of individual studies, including methet this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe anticipated methods for assessing risk of bias of individual studies, including methet will be done at the c combining data from studies, including any planned exploration of consistency (such as propriate or combining data from the synthesis, describe planned sum	Information sources         9         8         Describe all intended information sources (such as electronic databases, contact with study, authors, trial registers on literature sources) with planned dates of coverage           Search strategy         10         16         Present draft of search strategy to be used for at least one electronic databases, including planned limits, such that it repeated           Study records:         Data         11a         8-10         Describe the mechanism(s) that will be used for selecting studies (such as two independent reduptions of the second state the process that will be used for selecting studies (such as ploting forms, den ging ependent v, in duplicate), process         11b         8-10         Describe planned method of extracting data from reports (such as ploting forms, den ging ependently, in duplicate), process           Data titems         12         9         Ust and define all variables for which data will be sought, including prioritisation of the second strategy and soft state how this information will be used individual studies, including widther this will be done at the advise of the study level, or bots; state how this information will be used in data synthesis         13a         8,10         Ust and define all outcomes for which data will be sought, including prioritisation of the second strategy and additional outcomes, the individual studies, including widther this will be done at the individual studies.         13a         8,10         Describe anticipated methods for assessing risk of bias of individual studies, including widther this will be done at the individual studies.         15a         10         Describe any propose			BMJ Open by ja. cg be
Information sources98Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or of literature sources) with planned dates of coverageSearch strategy1016Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it co repeatedStudy records: 	Information sources       9       8       Describe all intended information sources (such as electronic databases, contact wind stady authors, trial registers on literature sources) with planned dates of coverage         Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it repeated         Study records:			-2022-01 yright, ir
Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it correpeated         Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout graph between the mechanism strategy to be used for selecting studies (such as two independent records);       In the mechanism strategy         Selection       11b       8-10       State the process that will be used for selecting studies (such as two independent records);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting forms);       Intervention of the mechanism strategy to be used for selecting studies (such as piloting forms, domesting for obtaining and confirming data from investigators       Intervention of the mechanism strategy to be used for which data will be sought, including prioritisation of the mechanism study level, or both; state how this information will be used in data synthesis       Intervention of the mechanism study level, or both; state how this information will be used in data synthesis       Intervention of the mechanism study level, or both; state how this information will be used in data synthesis of the used study level, or both; state how this information will be used in data synthesis of the used study	Search strategy       10       16       Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it repeated         Study records:	iformation sources	9 8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other gre literature sources) with planned dates of coverage
Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout the process that will be used for selecting studies (such as two independent records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       Image: State the process that will be used for selecting studies (such as two independent records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       Image: State the process that will be used for selecting studies (such as piloting forms, down of the process of the process of the obtaining and confirming data from investigators of obtaining and confirming data from investigators of obtaining and simplifications       Image: State the process of the proceses of the process of the proces of the process of the p	Study records:       Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout the process that is, screening, eligibility and inclusion in meta-analysis)       The process of that is, screening, eligibility and inclusion in meta-analysis)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as two independent reports)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, domethod perces), any pre-planned data and simplifications         Data items       12       9       List and define all outcomes for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesis         Outcomes and       13       8,10       List and define all outcomes for which data will be used in data synthesis         Tisk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including with the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measeres, the thods of handling data ar combining data from studies, including any planned exploration of consistency (suchas as tudies) for insudies, including any planned asesestive for on	earch strategy	10 16	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated
Data management11a8-10Describe the mechanism(s) that will be used to manage records and data throughout is be eview managementSelection process11b8-10State the process that will be used for selecting studies (such as two independent retrieves) through each phase of the (that is, screening, eligibility and inclusion in meta-analysis)Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, domesing for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding forms, domesing and simplificationsOutcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of 	Data       11a       8-10       Describe the mechanism(s) that will be used to manage records and data throughout be been with the process of that is, screening, eligibility and inclusion in meta-analysis)         Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, dome of the process for obtaining and confirming data from investigators for obtaining and confirming data from investigators       Image: script of the planned method of extracting data from investigators for obtaining former, and simplifications         Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding formerces), any pre-planned data and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the script of the s	tudy records:		Se a
Selection process11b8-10State the process that will be used for selecting studies (such as two independent rewers) through each phase of the (that is, screening, eligibility and inclusion in meta-analysis)Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, dometication, an for obtaining and confirming data from investigatorsand simplification), an for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding beam ces), any pre-planned data as and simplificationsOutcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned exploration of consistency (such as to combining data from studies, including any planned expl	Selection       11b       8-10       State the process that will be used for selecting studies (such as two independent redefined in the second process of the second proces of the second process of the second proces of the secon	Data 1 management	11a 8-10	Describe the mechanism(s) that will be used to manage records and data throughout the beview
Data collection process11c8-10Describe planned method of extracting data from reports (such as piloting forms, do fighe pendently, in duplicate), an for obtaining and confirming data from investigatorsData items129List and define all variables for which data will be sought (such as PICO items, funding and simplificationsOutcomes and 	Data collection       11c       8-10       Describe planned method of extracting data from reports (such as piloting forms, do fight dependently, in duplicate), for obtaining and confirming data from investigators         Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding storces), any pre-planned dat. and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the study level, or both; state how this information will be used in data synthesis       10         Risk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be quantitatively synthesised       10         15b       10       Describe criteria under which study data will be quantitatively synthesised       10         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)       15c         15d       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within se	Selection 1 process	11b 8-10	State the process that will be used for selecting studies (such as two independent red awars) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data items129List and define all variables for which data will be sought (such as PICO items, funding both ces), any pre-planned data and simplificationsOutcomes and138,10List and define all outcomes for which data will be sought, including prioritisation of the prioritizationRisk of bias in1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesis15Data synthesis15a10Describe criteria under which study data will be quantitatively synthesised combining data from studies, including any planned exploration of consistency (such as IC Kendall's τ)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses meteregression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Data items       12       9       List and define all variables for which data will be sought (such as PICO items, funding burgers), any pre-planned data and simplifications         Outcomes and       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the sought and additional outcomes, prioritization         Risk of bias in       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the individual studies         Data synthesis       15a       10       Describe criteria under which study data will be guantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data ar combining data from studies, including any planned exploration of consistency (such as general-regression)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses general-regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADEF         * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group Profesere	Data collection 1 process	11c 8-10	Describe planned method of extracting data from reports (such as piloting forms, do sind be pendently, in duplicate), any proce for obtaining and confirming data from investigators
Outcomes and prioritization138,10List and define all outcomes for which data will be sought, including prioritisation of to be sought, including prioritisation of to be sought, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisRisk of bias in individual studies1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the c study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, aethods of handling data and 	Outcomes and prioritization       13       8,10       List and define all outcomes for which data will be sought, including prioritisation of the fibe of the sought, including prioritisation of the sought, including whether this will be done at the individual studies         Risk of bias in individual studies       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, nethods of handling data are combining data from studies, including any planned exploration of consistency (suclease for end the synthesis is not appropriate, describe the type of summary planned         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses methor regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         0       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         0       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         0       If stributed under a Creative Commons Attribution Licence 4.0.	ata items	12 9	List and define all variables for which data will be sought (such as PICO items, funding for the sources), any pre-planned data assumption and simplifications
Risk of bias in1410Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the original studiesIndividual studiesstudy level, or both; state how this information will be used in data synthesisImage: Study level, or both; state how this information will be used in data synthesisData synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as sensitivity or subgroup analyses meta-regression)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Risk of bias in individual studies       14       10       Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the study level, or both; state how this information will be used in data synthesis         Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised         15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, arethods of handling data are combining data from studies, including any planned exploration of consistency (success is Kendall's τ)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses smeeter regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within s         Confidence in 17       10       Describe how the strength of the body of evidence will be assessed (such as GRADEF)         evidence       *       It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Green attributed under a Creative Commons Attribution Licence 4.0.         Fram: Shameser L. Moher D. Clarke M. Cherci D. Liberati A. Battigr	utcomes and rioritization	13 8,10	List and define all outcomes for which data will be sought, including prioritisation of the and additional outcomes, with ration
Data synthesis15a10Describe criteria under which study data will be quantitatively synthesised15b10If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as log Kendall's τ)15c10Describe any proposed additional analyses (such as sensitivity or subgroup analyses geneta-regression)15dN/AIf quantitative synthesis is not appropriate, describe the type of summary planned	Data synthesis       15a       10       Describe criteria under which study data will be quantitatively synthesised       is	isk of bias in ndividual studies	14 10	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcom study level, or both; state how this information will be used in data synthesis
<ul> <li>15 10 If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and combining data from studies, including any planned exploration of consistency (such as the Kendall's τ)</li> <li>15c 10 Describe any proposed additional analyses (such as sensitivity or subgroup analyses general-regression)</li> <li>15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned</li> </ul>	15b       10       If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data are combining data from studies, including any planned exploration of consistency (such as is Kendall's τ)         15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses geneth-regression)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         veidence       15       10       Describe read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Greater a Creative Commons Attribution Licence 4.0.         From:       Shamesaer L. Moher D. Clarko M. Charsi D. Libergti A. Patticraw M. Shakalla B. Stewart L. DBIGMA B. Creater D. Stewart L.	ata synthesis	15a 10	Describe criteria under which study data will be quantitatively synthesised
15c 10 Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression) 15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned and service of service of service of summary planned and service of	15c       10       Describe any proposed additional analyses (such as sensitivity or subgroup analyses methods)         15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies) selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         evidence       15       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Greater is the strength of Licence 4.0.         From:       Shamcaar I. Moher D. Clarka M. Charci D. Liberati A. Patticrony M. Shekalla B. Stawart I. DBISMA B. Group. Proferred expecting in temp for expecting with sheares in analysis.	1	15b 10	If data are appropriate for quantitative synthesis, describe planned summary meas 🛱 es, 🚋 ethods of handling data and methoc combining data from studies, including any planned exploration of consistency (such as is Kendall's τ)
15d N/A If quantitative synthesis is not appropriate, describe the type of summary planned 🚊 S	15d       N/A       If quantitative synthesis is not appropriate, describe the type of summary planned         Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across stuclies selective reporting within s         Confidence in       17       10       Describe how the strength of the body of evidence will be assessed (such as GRADE)         cumulative	1	15c 10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses meta-regression)
	Meta-bias(es)       16       N/A       Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition condition bias across studies selective reporting within second condition bias across studies selective reporting within second condition bias across studies across studies selective reporting within second condition condition bias across studies across studies selective reporting within second condition condition bias across studies across studies across studies selective reporting within second condition condition bias across studies across	1	15d N/A	If quantitative synthesis is not appropriate, describe the type of summary planned 🚆 🦉
Meta-bias(es) 16 N/A Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within stud	Confidence in 17 10 Describe how the strength of the body of evidence will be assessed (such as GRADE) cumulative evidence * It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Gr distributed under a Creative Commons Attribution Licence 4.0.	/leta-bias(es)	16 N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies
Confidence in 17 10 Describe how the strength of the body of evidence will be assessed (such as GRADE) cumulative evidence	* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for importan on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Go distributed under a Creative Commons Attribution Licence 4.0.	onfidence in umulative vidence	17 10	Describe how the strength of the body of evidence will be assessed (such as GRADE) 2



a systematic revie	ew pro	otocol*	
Section and topic	ltem No	Page No	Checklist item ទី។ ភ ឆ្លូ ច្រុ
ADMINISTRATIVE INI	FORMA	TION	is reig reig
Title:			ateo
Identification	1a	1,2	Identify the report as a protocol of a systematic review
Update	1b	N/A	If the protocol is for an update of a previous systematic review, identify as such 한 한 호
Registration	2	3	If registered, provide the name of the registry (such as PROSPERO) and registration မြားစြာဆိုး
Authors:			
Contact	3a	1	Provide name, institutional affiliation, e-mail address of all protocol authors; providaging gical mailing address of correspondinauthor
Contributions	3b	12	Describe contributions of protocol authors and identify the guarantor of the review
Amendments	4	N/A	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments
Support:			aini
Sources	5a	11	Indicate sources of financial or other support for the review
Sponsor	5b	11	Provide name for the review funder and/or sponsor
Role of sponsor or funder	5c	11	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol
INTRODUCTION			ar tec
Rationale	6	4,5	Describe the rationale for the review in the context of what is already known 💙 💈 🔁
Objectives	7	6	Provide an explicit statement of the question(s) the review will address with reference to barticipants, interventions, compar and outcomes (PICO)
METHODS			
Eligibility criteria	8	6-8	Specify the study characteristics (such as PICO, study design, setting, time frame) and rerent to characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review
Information sources	9	8	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other generators of coverage

Page 21 of 23

3 4

34

44 45

			BMJ Open g g
			opyri
			ght, ir
Search strategy	10	16	Present draft of search strategy to be used for at least one electronic database, including lanned limits, such that it could be repeated
Study records:			
Data management	11a	8-10	Describe the mechanism(s) that will be used to manage records and data throughou the review
Selection process	11b	8-10	State the process that will be used for selecting studies (such as two independent rexiews) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)
Data collection process	11c	8-10	Describe planned method of extracting data from reports (such as piloting forms, do and performed by the pendently, in duplicate), any processes for obtaining and confirming data from investigators
Data items	12	9	List and define all variables for which data will be sought (such as PICO items, funding second), any pre-planned data assumptions and simplifications
Outcomes and prioritization	13	8,10	List and define all outcomes for which data will be sought, including prioritisation of a finand additional outcomes, with rationale
Risk of bias in individual studies	14	10	Describe anticipated methods for assessing risk of bias of individual studies, including where this will be done at the outcome or study level, or both; state how this information will be used in data synthesis
Data synthesis	15a	10	Describe criteria under which study data will be quantitatively synthesised 🛛 🛓 🧕
	15b	10	If data are appropriate for quantitative synthesis, describe planned summary measures, whethods of handling data and methods of combining data from studies, including any planned exploration of consistency (such the subscripts is Kendall's τ)
	15c	10	Describe any proposed additional analyses (such as sensitivity or subgroup analyses net a-regression)
	15d	N/A	If quantitative synthesis is not appropriate, describe the type of summary planned 👸 🔓
Meta-bias(es)	16	N/A	Specify any planned assessment of meta-bias(es) (such as publication bias across studies selective reporting within studies)
Confidence in cumulative evidence	17	10	Describe how the strength of the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) in the body of evidence will be assessed (such as GRADE) is a such as GRADE in the body of evidence will be assessed (such as GRADE) is a such as GRADE in the body of evidence will be assessed (such as GRADE).
* It is strongly recom on the items. Amend distributed under a C From: Shamseer L, M analysis protocols (PE	mended Iments t Creative	I that this to a review Common Clarke M,	checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cige when available) for important clarification w protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is s Attribution Licence 4.0.
		, 2020, 2,	Bibliographique de

